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        In the female, vascular endothelial growth factor A (VEGFA) isoforms regulate 
follicle development and affect the initial primordial follicle pool. In male rodent testes, 
they are involved in the development of vasculature and seminiferous cords. The 
objective of the current study was to evaluate effects of Sertoli and Granulosa cell-
specific production of VEGFA isoforms on vascular development and gonadal 
morphogenesis. We used a DMRT1-cre crossed to a floxed VEGFA mouse to determine 
potential phenotypes in male Sertoli-cell (VEGFA-DSertG) and female Granulosa-cell 
(VEGFA-DGranG) specific knockouts. In females, we found smaller ovarian weight, 
fewer corpus luteums (CLs) with some abnormal CL morphology, and 55% reduction in 
estrogen in the VEGFA-DGranG compared to controls. The number of days mated until 
parturition was 12 days longer in VEGFA-DGranG X VEGFA-DSertG pairs versus 
control females mating with control males. In males, the weight of body, testes and 
epididymides in VEGFA-DSertG mice were significantly reduced than those from the 
controls. The morphology of epididymis and prostate appeared to be different with less 
tubules and branching, respectively compared to controls. Serum testosterone levels in 
VEGFA-DSertG tended to be higher than those in controls. Bcl-2 mRNA and Bcl-2/Bax 
in VEGFA-DSertG testis tended to be higher than that in controls. Sin3a mRNA within 
testis was higher in those three VEGFA-DSertG males with high serum testosterone 
concentration than controls. Therefore, we conclude that lack of VEGFA in Granulosa 
and Sertoli cells alters reproductive organ morphogenesis, reduces gonadal and male 
accessory gland organ weights, alters steroidogenesis and creates sub-fertility in mice. 
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Chapter 1 
Literature Review 
Introduction 
        Over the past decades, fertility has sharply declined and the proportion of couples 
who need infertility treatment has increased tremendously (Leridon et al., 2008). About 
one-half of infertility cases are due to male factors such as cryptorchidism, 
oligozoospermia and the other one-half are attributed to female such as uterine and pelvic 
abnormalities, secondary infertility, polycystic ovarian syndrome. Currently increased 
human infertility suggests that significant reproductive health problems exist 
(Skakkebaek et al., 2005). 
        VEGFA is also present during testis morphogenesis and expressed by Sertoli cells 
which play an important role in the testis formation and function. The incidence of male 
reproductive disorders including impaired spermatogenesis, undescended testis, 
hypospadia and testicular cancer has been increasing during recent decades. These 
reproductive disorders could be called testicular dysgenesis syndrome (TDS) (Funke et 
al., 2010). One potential cause of TDS may be due to disruptions in embryonic gonadal 
development. Our laboratory has demonstrated that inhibition of VEGFA angiogenic 
isoforms arrested both testis cord formation and vascular development in mice (Bott et al., 
2006). Excess of VEGFA angiogenic isoform resulted in less organized and poorer 
seminiferous cords in rat testis (Baltes-Breitwisch et al., 2010). VEGFA signal 
transduction inhibitors reduced the endothelial cell migration during testis formation in 
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mice (Bott et al., 2010). Furthermore, overexpression of VEGFA in transgenic mice 
results in infertility (Korpelainen et al. 1998). 
        Vascular Endothelial Growth Factor A (VEGFA) is paracrine growth factor 
responsible for blood vessel development as well as endothelial cell migration. VEGFA 
expression and production within the ovary are critical for normal reproductive function. 
In the female, VEGFA plays an important role in the cyclic growth of ovarian follicles 
and in the development and maintenance of corpus luteum (CL) by mediating ovarian 
angiogenesis. Defects in angiogenesis may cause some disorders such as anovulation, 
pregnancy loss, ovarian hyperstimulation syndrome, and ovarian neoplasms (Geva and 
Jaffe, 2000). Previous studies in our laboratory demonstrated that VEGFA is involved in 
primordial follicle activation, maturation and survival (McFee et al., 2009; Artac et al., 
2009). 
        The objective of my research is to evaluate the effect of granulosa and Sertoli cell-
specific production of VEGFA isoforms on vascular development and gonadal 
morphogenesis. 
Testis morphogenesis 
        There are at least five morphological stages of testis development: (1) development 
of a genital ridge, (2) formation of an indifferent or bipotential gonad, (3) sex 
determination, (4) induction of testicular cords in the testis, and (5) development of a 
functional testis (Fig. 1) (Cupp and Skinner 2005). 
 
    3 
 
Development of a genital ridge 
        Development of a genital ridge occurs in both male and female. Formation of the 
genital ridge and urogenital system from the intermediate mesoderm starts at 9-9.5 days 
post coitus (dpc) in the mouse. In male, Woffian duct formation is driven by lateral 
mesoderm and develops from the mesonephric duct (Grobstein, 1953). Several genes 
such as Lhx1 (LIM homeobox 1), Wilms’ tumor 1 (Wt1) and Emx2 are expressed in the 
urogenital ridge by 9.5 dpc in the mouse and contribute to the development of the 
indifferent gonads (Shawlot et al., 1995; Kreidberg et al., 1993; Miyamoto et al., 1997). 
At approximately 10.5 dpc, the gonad forms as an outgrowth of the genital ridge in both 
male and female (Brennan et al., 2002). Then, the coelomic epithelium of the urogenital 
ridges will develop to the indifferent gonads (Cui et al., 2004).  
Formation of an indifferent gonad 
      The second stage of testis morphogenesis is the development of indifferent gonad.  In 
the mouse, the indifferent gonad becomes visible at 10 dpc but still cannot be identified 
as a testis or ovary (Swain and Lovell-Badge, 1999). The indifferent gonad can 
differentiate to testis or ovary depending on the transcription factors expressed in the 
differentiating somatic cells of the coelomic epithelium (Cupp and Skinner, 2005). In XY 
gonads, primordial germ cells (PGCs) migrate long distances from the yolk sac to the 
prospective gonads (Aman and Piotrowski, 2010). The migration of PGCs in the mouse is 
induced at the interface between extraembryonic and embryonic tissues. Bone 
morphogenetic protein (BMP) 4 and 8 signaling from the extraembryonic ectoderm is 
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required for this induction (Kunwar et al., 2006). The migration of PGCs is from the gut 
to somatic gonadal mesoderm to colonize the gonads (Bendel-Stenzel et al. 1998, 
Molyneaux and Wylie, 2004). Kit ligand (KL) plays a critical role in regulation of PGC 
survival by preventing PGC apoptosis. Kit Ligand also promotes PGC migration due to 
its function as an adhesion factor (De and Pesce, 1994; De et al., 2009). 
Sex Determination 
        The third stage of testis development is sex determination. Testis determination is 
controlled by Sry (Sex-determining Region Y). Sry gene is male sex-determining gene on 
the Y chromosome (Martineau et al., 1997). Expression of Sry transgenic in XX mice 
results in the initiation of testis cord formation (Koopman et al., 1991; Eicher et al., 
1995). In the mouse, the Sry gene is expressed at 10.5 dpc and ceases after 12.5 dpc. Sry 
stimulates expression of genes such as Sry box9 (Sox9) which cause the differentiation of 
the Sertoli cell from coelomic epithelial cells (Karl and Capel, 1998). The Sertoli cell is 
the first cell to differentiate in the testis (Magre and Jost 1991). After differentiation, 
Sertoli cells move into the gonad and aggregate with primordial germ cells and start 
proliferate at 11.25 dpc in the mouse. Proliferation of Sertoli cells increases the size of 
testis and is determined by the expression of Sry (Schmahl et al. 2000; Schmahl and 
Capel 2003). 
Induction of testicular cords in the testis 
        The fourth stage is induction of testicular morphology and seminiferous cord 
formation. Testicular cord formation is an important event in establishing the adult testis 
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morphology. In the mouse after Sertoli cell differentiation, formation of testicular cords 
and sex-specific vascularization occur around 11.5 -12 dpc and are complete by 12.5 dpc 
(Martineau et al., 1997). First step in cord formation is aggregation of Sertoli cells with 
PGCs. The second step is the migration of mesonephric cells from the adjacent 
mesonephros to the differentiating testis (Cupp and Skinner 2005). Testis development is 
initiated by Sertoli cell differentiation and Sry expression. Testis failed to develop well-
differentiated testis cords when mesonephros was removed at 11.5 dpc (Buehr et al., 
1993). Migration of mesonephric cells is required for seminiferous cord formation 
(Merchant-Larios et al., 1993). It has been demonstrated that some paracrine growth 
factors such as Hepatocyte growth factor (HGF), Fibroblast growth factor 9 (Fgf9), 
neurotropin-3 (NT3), VEGF and Platelet-derived growth factors (PDGFs) are involved in 
mesonephric cell migration and cord formation (Ricci et al. 1999; Colvin et al. 2001; 
Cupp et al. 2003; Bott et al., 2006). In addition to surrounding the Sertoli-primordial 
germ cell aggregates to form testis cords, the migrating mesonephric cells may also 
initiate the formation of vasculature in the testis (Bott et al., 2008). Formation of 
testicular cords and sex-specific vasculature are the key morphological markers to 
distinguish a testis from an ovary.   
Development of a functional testis 
        The last step in testis morphogenesis is development of a functional testis. After 
seminiferous cord is formed, the other cells within the testis begin to differentiate. Sertoli 
cells produce the factors to initiate interstitial, peritubular, and Leydig cell differentiation 
(Cupp and Skinner, 2005). The peritubular cell surrounds and forms the exterior wall of 
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the seminiferous tubule. The peritubular and the Sertoli cells form the basement 
membrane surrounding the seminiferous tubule and their interactions are critical for germ 
cell development. The interstitial space outside the seminiferous tubules has the Leydig 
cells which are responsible for testicular steroid production (Skinner and Anway et al., 
2005). Estrogens and androgens have effects on testis growth, development of cell 
populations and differentiation of male reproductive tracts (Cupp and Skinner, 2005).  
Spermatogenesis 
        Spermatogenesis is the process of sperm formation and maturation. It occurs in the 
seminiferous epithelium of the testis and is characterized by continuous germ cell 
maturation towards the center of the seminiferous tubules. During this time male germ 
cells undergo both mitotic and then meiotic divisions (Ruwanpura et al., 2010). Specially, 
there is mitotic proliferation of spermatogonia, meiotic division of spermatocytes, 
differentiation of spermatids and final release of spermatozoa into the tubule lumen 
(Tripathi et al., 2009). Gonocytes in the postnatal testis arise from PGCs and then 
develop to spermatogonial stem cells (SSCs). The foundation of spermatogenesis is SSC 
(Phillips et al., 2010). Spermatogenic lineage development is referred to as the 
spermatogenic cycle (Clermont, 1972).  
        Spermatogonia are at the basement membrane of the seminiferous tubules. They are 
the primitive diploid germ cells (Phillips et al., 2010). Undifferentiated type A 
spermatogonia differ in the topographical arrangement on the seminiferous tubule 
basement membrane and can be subdivided into Asingle (As), Apaired (Apr) and Aaligned (Aal) 
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spermatogonia (Huckins, 1971). Differentiating spermatogonia (A1, A2, A3, A4 and B) 
are found at specific stages of the seminiferous epithelium (Oakberg, 1971). Type B 
spermatogonia develop to primary spermatocytes that then progress to meiosis. Two 
meiotic divisions lead to the formation of secondary spermatocytes and haploid 
spermatids respectively. Spermatids mature into spermatozoa which will be released from 
the seminiferous epithelium (Phillips et al., 2010). During normal spermatogenesis, 
apoptosis regulates the ratio of Sertoli cells to germ cell number. Apoptosis induces 
programmed cell death to eliminate the germ cells which fail to replicate their DNA 
accurately during cell division (Ruwanpura et al., 2010). 
Hormonal regulation of spermatogenesis 
The role of FSH in spermatogenesis 
        The size of the Sertoli cell population is set in early postnatal life and it is a major 
determinant of sperm output in the adult animal (Ruwanpura et al., 2010). FSH increases 
the proliferation of Sertoli cells (Sharpe et al., 2003); regulates the spermatogonial 
population in rodents (McLachlan et al. 2002) and has been demonstrated to be involved 
in spermatogonial survival (Beardsley & O’Donnell 2003; Ruwanpura et al. 2008a). An 
in vivo study demonstrated that FSH contributes to the proliferation of undifferentiated 
type A spermatogonia in immature testis cultures (Boitani et al., 1993). If FSH is 
suppressed then there is an increase in spermatogonial apoptosis in immature and adult 
rats (Ruwanpura et al. 2008a, b, 2010). Besides its role in regulation of spermatogonia 
population, FSH also plays roles in meiosis and spermiogenesis. Vihko et al. reported 
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that FSH is critical for the meiosis in the first wave of rat spermatogenesis (Vihko et al., 
1991). Hypogonadal (hpg) mice expressing transgenic FSH showed that FSH supports 
spermatogonial proliferation and the stimulation of meiotic and post-meiotic germ cell 
development (Haywood et al. 2003). 
The role of testosterone in spermatogenesis 
        In immature testes, testosterone is essential for gonadal maturation and testicular 
differentiation (Ruwanpura et al., 2010). Somatic Sertoli cells transduce signals from 
testosterone into the production of factors that are necessary for germ cells when they 
become spermatozoa (Walker and Cheng 2005). Only Leydig cells, peritubular cells and 
Sertoli cells express androgen receptor (AR). No AR is expressed in germ cells of the 
mature testis (Walker and Cheng 2005). It is demonstrated that testosterone is able to 
suppress Sertoli cell proliferative activity in vitro (Buzzard et al., 2003). Without 
testosterone, progressive germ cell degeneration begins during stage VII of the 
spermatogenic cycle (Walker and Cheng 2005). In the absence of androgen replacement, 
spermatogenesis is arrested during meiosis in Hpg male mice which lack both FSH and 
LH because of an inactivated mutation at the GnRH locus. Testosterone treatment also 
confers a qualitative recovery of spermatogenesis in Hpg mice (Holdcraft and Braun 
2004). AR Sertoli cell knockout mice appeared arrested at late spermatocytes, indicating 
that the completion of meiosis and spermatogenesis is in need of androgen in the first 
spermatogenic wave (Chang et al. 2004; De Gendt et al. 2004). Testosterone not only 
plays roles in regulation of spermatogonia, but also is important for meiosis and 
spermiogenesis in rodents (McLachlan et al. 2002; Haywood et al. 2003).  
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Ovarian Development and Differentiation 
        The undifferentiated or bipotential gonadal ridge appears at approximately 10.5 dpc 
between the coelomic epithelium and the mesonephros in the mouse. The fate of the 
gonad is determined by both male-promoting and female-promoting signals. Sry, Sox9, 
and fibrolast growth factor 9 (Fgf9) initiate testis differentiation in indifferent gonads. 
Wingless-type member 4 (Wnt4) and R-spondin 1 (RSPO1) promote indifferent gonads 
into ovary differentiation (Fig. 2) (DiNapoli and Capel et al., 2008). XX gonads do not 
have Sry, so the female promoting signals shut down the male signals and initiate ovarian 
development. The ovarian differentiation pathway involves the increase of the signaling 
of WNT4 by RSPO1, which up-regulates β-catenin. β-catenin up-regulates WNT4 and 
other proteins such as Follistatin (FST) (Edson et al., 2009). FST inhibits formation of 
the XY-specific coelomic vessel in XX gonads. WNT4/FST signaling inhibits 
downstream events of testis development. FST also plays a critical role in the survival of 
germ cells in ovary.  
Ovarian folliculogenesis  
        Autocrine, paracrine and endocrine factors contribute to ovarian folliculogenesis. 
Besides oocytes, granulosa cells and theca cells also develope and play critical roles in 
ovary. There are several steps in ovarian folliculogenesis: (1) formation of the primordial 
follicle, (2) Maintenance of primordial follicles and initial recruitment (3) preantral 
folliculogenesis, (4) theca formation and physiology, (5) antral follicle formation, (6) the 
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preovulatory follicle, cumulus expansion, ovulation, and luteinization (Fig. 3) (Edson et 
al., 2009). 
Formation of the primordial follicle 
        After migration of PGCs, oogonia undergo mitotic proliferation. Mouse germ cells 
are connected by intercellular bridges in the ovaries from 11.5 to 17.5 dpc (Pepling and 
Spradling et al., 1998). Around 13.5 dpc in the female mouse, the first wave of oogonia 
begin meiosis and finally arrest as diplotene oocytes close to birth (Bristol-Gould et al., 
2006). Individual oocytes in these nests lack surrounding somatic cells and majority of 
the oocytes will undergo apoptosis. Cysts undergo apoptosis between 20.5-22.5 dpc in 
mice, during which only about one third of the oocytes survive to form primordial 
follicles (Pepling and Spradling, 2001, Edson et al., 2009). Some oocytes survive after 
germ cell cluster breakdown. When those oocytes are individually surrounded by 
squamous pre-granulosa cells, primordial follicle formation occurs. This is the first stage 
of folliculogenesis and it occurs in the days immediately after birth in female mice 
(Edson et al., 2009). During early postnatal period in the rodent, the primordial follicles 
assemble. Primordial follicles consist of one oocyte and an incomplete layer of squamous 
pre-granulosa cells. These primordial follicles are surrounded by stromal-interstitial cells 
but no apparent theca cell layers or organized mesenchymal tissue (Skinner, 2005).  
Maintenance of primordial follicles and initial recruitment 
        Follicle recruitment is subdivided into two categories. The first one is initial 
activation of primordial follicles and it occurs throughout life until menopause. The 
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second one is cyclic recruitment of a limited number of small follicles from the growing 
cohort, from which a subset is selected for dominance and ovulation after puberty (Edson 
et al., 2009). The majority of primordial follicles exist in a quiescent state in which the 
oocyte is arrested in prophase I of meiosis. In sexually mature animals, follicles leave the 
arrested pool and transform from primordial to primary follicles (Bristol-Gould et al., 
2006). Morphological changes in granulosa cells from squamous to cuboidal are the 
histological marker for the transition from primordial to primary follicle. Several 
transcription factors and signaling pathways regulate this early step in folliculogenesis. 
NOBOX (newborn ovary homeobox), SOHLH1 (spermatogenesis and oogenesis helix-
loop-helix 1), and SOHLH2 are key transcription factors during the transition from 
primordial to primary follicles (Edson et al., 2009). Transgenic mice lacking Nobox, 
Sohlh1, or Sohlh2 have defects in the transition from primordial to primary follicle and 
are infertile (Choi et al., 2008; Hao et al., 2008; Pangas et al., 2006; Rajkovic et al., 
2004). Nobox
-/-
, Sohlh1
-/-
 Sohlh2
-/-
 mice have the similar numbers of germ cell clusters 
and primodial follicles as controls. However, by postnatal day 3, these transgenic mice 
lack primary follicles and experience an early postnatal loss of oocytes. It is reported that 
KIT ligand/KIT signaling contributes to the transition from primordial to primary follicle 
and induces the PI3K/AKT pathway which lead to phosphorylation and inactivation of 
forkhead box O3 (Foxo3). Foxo3 is a key oocyte factor critical for suppressing primordial 
follicle activation (Castrillon et al., 2009). 
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Preantral folliculogenesis 
        Preantral folliculogenesis is characterized by oocyte growth, granulosa cell 
proliferation and acquisition of theca cell layer. Preantral follicle growth in mice starts at 
10 to 12 days after birth when a cohort of developing follicles reaches the second stage of 
folliculogenesis. Secondary follicles contain oocytes in the middle of their growth stage 
which are surrounded by two or more layers of granulosa cells (Edson et al., 2009). The 
communication between granulosa cells and oocytes is bidirectional and occurs 
throughout follicular development (Eppig et al., 2002). Specifically, the oocyte depends 
on its relationship with accompanied somatic granulosa cells to support its growth and 
regulate the progression of meiosis. At the same time, oocytes stimulate granulosa cell 
proliferation, differentiation, and function. For example, Oocyte-secreted members such 
as the transforming growth factor β (TGF β) family, growth differentiation factor (GDF)-
9, and bone morphogenic protein (BMP)-15 play critical roles in early follicular 
development (Dong et al., 1996; Dube et al., 1998; Elvin et al., 1999). These oocyte-
derived paracrine factors also stimulate follicular somatic cell proliferation and 
steroidogenesis (Elvin et al., 1999; Solovyeva et al., 2000).  
Theca formation and physiology 
        Once the follicle develops two layers of granulosa cells, a layer of theca cells 
differentiate to the outermost layer (Hirshfield, 1991a). The theca interna is a layer of 
highly vascularized steroidogenic cells adjacent to the basal lamina, while the theca 
externa is a loosely organized band of non-steroidogenic cells between the theca interna 
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and the interfollicular stroma. The theca interna is composed of mitochondria with 
tubular cristae, smooth endoplasmic reticulum, and abundant lipid vesicles (Magoffin, 
2005). The theca externa contains fibroblasts, smooth muscle-like cells, and macrophages, 
which are important during ovulation (Hirshfield, 1991b). Mouse follicles develop to the 
large antral stage containing fully grown oocytes by 18–24 days after birth (Eppig et al., 
2002).  
Antral follicle formation 
        During antral folliculogenesis, multiple small fluid-filled spaces combine to form a 
single antral cavity. Two functionally distinct granulosa cell populations are separated by 
the antral cavity. At the wall of the follicle the newly formed mural granulosa cells are 
critical for steroidogenesis and ovulation while the antral granulosa cells surround the 
oocyte which promotes its growth and development (Edson et al., 2009). FSH is essential 
for antral follicular development (Kumar et al., 1997). FSH inhibits granulosa cell 
apoptosis and follicular atresia and is necessary for antral granulosa cell proliferation, 
estradiol production, and LH receptor expression (Chun et al., 1996; Richards, 1994).  
The preovulatory follicle, cumulus expansion, ovulation, and luteinization 
        The majority of follicle populations in the growing pool undergo atresia and only a 
few antral follicles in a developing cohort arrive at the preovulatory stage. Increased 
follicular estradiol production increases pituitary LH and eventually induce the LH surge. 
Preovulatory follicles produce luteinizing hormone/choriogonadotropin receptor 
(LHCGR) at high concentrations in granulosa cells which enable them to respond to the 
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LH surge. LH surge initiates downstream events leading to oocyte meiotic resumption, 
cumulus expansion, follicle rupture and final terminal differentiation of the remaining 
granulosa and theca cells to form the CL (Edson et al., 2009). Ovulation is a complex 
LH-induced process that allows the release of an oocyte. The proper formation of an 
extracellular hyaluronan (HA) rich matrix by the cumulus oocyte complex (COC) is 
critical for ovulation. Genes induced by LH surge and essential for proper expansion are 
hyaluronan synthase 2 (HAS-2) and cyclooxygenase-2 (COX-2). They control the 
synthesis of hyaluronan and prostaglandins (Richards, 2005). After follicle rupture and 
release of the cumulus-oocyte complex, the remaining granulosa and theca cells 
differentiate to form the CL. The CL is an endocrine structure responsible for secreting 
progesterone to stimulate the uterus and maintain pregnancy (Edson et al., 2009).  
Vascular Endothelial Growth Factor 
        The Vegf family comprises five members, including Vegfa, Vegfb, Vegfc, Vegfd 
(Figf, c-fos-induced growth factor) and placenta growth factor (Pgf). The significant one 
of VEGF family is VEGFA (Tammela et al., 2005). It is an endothelial cell-specific 
mitogen driven from arteries, veins and lympatics in vitro. VEGFA is an important 
regulator of both developmental and tumorigenic angiogenesis (Grunstein et al., 2000). It 
plays an essential role in embryonic vasculogenesis and angiogenesis in the mouse. It is 
also involved in skeletal growth and endochondral bone formation and angiogenesis in 
endocrine glands (Ferrara, et al., 2003; Ferrara, 2004).  
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VEGFA gene 
        The human VEGFA gene is located on chromosome 6p21.3 and is organized in 
eight exons, separated by seven introns (Houck et al, 1991; Tischer et al., 1991; Vincenti 
et al., 1996) and can be alternatively spliced to produce pro-angiogenic (angiogenic) or 
anti-angiogenic (inhibitory) isoforms by different factors (Fig. 4) (Harper and Bates, 
2008). VEGFA is a heparin-binding homodimeric glycoprotein of 45 kDa (Ferrara and 
Henzel, 1989).  
VEGFA isoforms 
       VEGFA isoforms are generated by alternate splice-site selection in the terminal exon 
(Nowak et al., 2008). Alternative exon splicing results in proangiogenic or angiogenic 
polypeptides of 111, 121, 145, 148, 165, 183, 193, 189, and 206 and the anti-angiogenic 
or inhibitory polypeptides 189b, 183b, 165b, 145b, 121b, acids for human (Ferrara et al., 
1991; Woolard et al., 2004; Harper and Bates, 2008). In rodent and domestic livestock, 
VEGFA isoform contains one less amino acid than the human VEGFA isoforms 
(Grunstein et al., 2000). Alternate 5’and 3’splice site selection in exons 6, 7 and 8 
generate multiple isoforms (Haper and Bates, 2008). Two mRNA isoform families are 
generated. Proximal splice-site selection (PSS) in exon 8 results in pro-angiogenic 
VEGFAxxx isoforms (xxx is the number of amino acids), while distal splice-site 
selection (DSS) results in anti-angiogenic VEGFAxxxb isoforms. SR protein splicing 
factors including ASF/SF2, SRp40 and SRp55 regulate the VEGFA splicing. Both 
    16 
 
ASF/SF2 and SRp40 favored PSS, but SRp55 upregulated VEGFAxxxb (DSS) isoforms 
(Nowak et al., 2008).  
Angiogenic isoform 
       VEGFA angiogenic isoforms have the exon 8a (Nowak et al., 2008). VEGFA165 
(VEGFA164 in rodent) was the first VEGFA isoform discovered in humans (Ferrara and 
Henzel, 1989). VEGFA164 is the predominant VEGFA angiogenic isoform. It is a 
multifunctional cytokine that is necessary for normal vascular development. It has 
potential vascular permeable activity, stimulates endothelial cell migration and is 
mitogenic for endothelial cells. It also re-programs endothelial cell gene expression and is 
an endothelial cell survival factor (Nagy et al., 2003). VEGFA165 lacks the residues 
encoded by exon 6, however, VEGFA121 does not have the residues encoded by exons 6 
and 7 (Ferrara, 2004). In mouse, due to the possession of exon 7, VEGFA164 results in 
increased heparin-binding affinity compared to VEGFA120. VEGFA188, containing both 
exons 6 and 7, leads to a dramatic increase in charge and extracellular matrix (ECM) 
association compared to the VEGFA164 and VEGFA120 (Grunstein et al., 2000).  
Anti-angiogenic isoform 
        VEGFA anti-angiogenic or inhibitory isoforms have the exon 8b (Nowak et al., 
2008). In 2002, Bates et al. identified a VEGFAxxxb isoform: VEGFA165b in human (in 
rodent VEGFA164b). They found that VEGFA165b inhibits VEGFA165-mediated 
proliferation, migration of endothelial cells and vasodilatation of mesenteric arteries. The 
results of their research suggest that VEGF165b may be anti-angiogenic. VEGFAxxxb 
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isoforms are expressed in many tissues (Bates et al., 2002). VEGFAxxxb isoforms bind 
to VEGFR2 (KDR), but lead a poorly activated kinase and weak downstream signal 
transduction. VEGFA165b does not increase chronic microvascular permeability in vivo, 
and reduces conditionally immortalized human glomerular endothelial cell monolayer 
permeability in vitro. VEGFA165b also inhibits angiogenesis in vivo in the rat mesentery. 
Moreover, VEGFA165b suppresses physiological angiogenesis in mammary tissue in 
transgenic mice and pathological angiogenesis in murine tumour models (Harper and 
Bates, 2008). All these studies suggest that VEGFAxxxb isoforms have an opposite 
function compared to VEGFA angiogenic isoforms. 
VEGFA receptors 
        VEGFA binds two related tyrosine kinases receptors: FMS-like tyrosine kinase1 
(FLT1, also known as VEGFR1) and kinase insertion domain protein receptor (KDR, 
also known as VEGFR2 and FLK1). The major mediator of the mitogenic, angiogenic 
and permeability effects of VEGFA is KDR. Also KDR is involved in mediating 
endothelial cell proliferation, survival and vascular permeability. In contrast, FLT1 may 
play an inhibitory role by sequestering VEGFA and preventing its interaction with KDR. 
In addition to these tyrosine kinases receptors, VEGFA also interacts with a family of 
coreceptors: the neuropilins (Ferrara, 2004). 
FLT1 
        Although Flt1 was the first VEGFR to be identified, the precise function of this 
molecule is unclear. Recent evidence indicates that the controversial reports may be due 
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to the fact that Flt1 functions and signaling properties are dependent on the 
developmental stage and the cell type such as endothelial vs. hematopoietic cells (Ferrara, 
et al., 2003; Ferrara, 2004). In response to VEGFA, Flt1 reveals a weak tyrosine 
autophosphorylation (de Vries et al., 1992, Waltenberger et al., 1994). One study 
reported that Flt1 activation causes inhibition of VEGFR2-dependent endothelial cell 
proliferation and the pathway is PI3 kinase dependent (Zeng et al., 2001). Other studies 
indicated that Flt1 interacts with different signal-transducing proteins and generate a 
mitogenic signal (Landgren et al., 1998; Maru et al., 1998).  
KDR 
        VEGFA angiogenic isoforms act primarily through VEGFR2 or KDR to initiate 
multiple downstream signal pathways. VEGFA angiogenic isoforms stimulate robust 
phosphorylation of tyrosine 1175, resulting in the activation of phospholipase Cγ (Fig. 5) 
(Harper and Bates, 2008). Phospholipase Cγ activates protein kinase C which results in 
the activation of Ras or Raf, mitogen-activated protein kinase (MAPK) and extracellular-
signal-regulated kinase-1/2 (ERK1/2). The result of ERK phosphorylation is endothelial 
cell proliferation. PLCγ also activates PKC via diacylglycerol (DAG) and then increase 
concentrations of intracellular calcium (Shu et al., 2002). Besides PLCγ, the adaptor 
molecule Shb binds to phosphorylated Tyr1175 of KDR. Tyr1173/1175 is coupled to 
VEGFA-induced PI3K activation. PI3K then activates the serine/threonine kinase 
AKT/PKB and mediates survival of the endothelial cells. AKT/PKB also regulates nitric 
oxide (NO) production by phosphorylation and activation of endothelial NO synthase 
(eNOS). ENOS regulates vascular permeability. The p38MAPK and FAK pathways are 
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also postulated to affect actin reorganization and focal adhesion turnover to influence 
migration. Heat-shock protein-27 (HSP27) is phosphorylated by p38MAPK. It is a 
molecular chaperone that positively regulates VEGFA-induced actin reorganization and 
migration. Several of these VEGFA signal transduction pathways may interact with each 
other to initiate endothelial cell differentiation, migration, proliferation and survival 
(Olsson et al., 2006).  
        Activation of KDR is phosphorylated by binding VEGFA anti-angiogenic isoforms; 
however different tyrosine residues show that it may not simply be an inactive competing 
inhibitor. Phospho-peptide mapping and site-specific phospho-antibody experiments 
show that VEGFA anti-angiogenic isoforms only partially activate KDR suggesting a 
partial intracellular rotation. This results in a rapid closure of the ATP binding site and 
fast inactivation that lead to a poorly activated kinase and weak, transient 
phosphorylation of ERK1 and ERK2 (Fig. 5) (Harper and Bates, 2008). This suggests 
that VEGFA anti-angiogenic isoforms initiate a poor and weak downstream signal. 
The Role of VEGFA in gonads 
The role of VEGFA in the ovary 
        Angiogenesis is a key aspect of normal cyclical ovarian function. Both follicular 
growth and the development of the CL are dependent on the proliferation of new 
capillary vessels (Ferrara, 2004). It is demonstrated that the VEGFA mRNA expression is 
also temporally and spatially associated with the proliferation of blood vessels in the 
ovary (Phillips et al., 1990; Ravindranath et al., 1992). VEGFA stimulates 
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neovascularization, regulates vascular permeability and is one of the key factors that 
regulate angiogenesis in the ovary (Kaczmarek et al., 2005).  
        Follicle activation is related to increased VEGFA and increased blood vessel 
extension (Mattioli et al., 2001). One in vitro study showed that direct ovarian 
administration of VEGFA significantly increased the number of preantral follicles in the 
rat ovary suggesting that VEGFA regulates the early follicle growth (Danforth et al., 
2003). Other research has demonstrated that endogenous VEGFA is essential for 
primordial follicle survival in the rodent (Roberts et al., 2007). Iijima et al., demonstrated 
that VEGFA angiogenic isoform promoted ovarian follicular angiogenesis, stimulated 
follicular development and increased the numbers of oocytes ovulated in mature cycling 
rats (Iijima et al., 2005).  
        VEGFA promoted the primary into secondary follicle transition in bovine follicles 
activated in vitro. Thus, VEGFA plays a stimulatory role in early preantral follicular 
growth in cattle (Yang and Fortune et al., 2007). In nonhuman primates, inhibition of 
VEGFA and KDR either suppresses follicular development or prevents ovulation 
(Zimmermann et al., 2001; Zimmermann et al., 2002). Zimmermann’s research showed 
that injection of VEGFA antagonist into the pre-ovulatory follicle in rhesus monkey 
caused half of the animals not to ovulate. This indicates VEGFA may also stimulate 
ovulation in addition to follicle progression (Zimmermann et al., 2002).  
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Our laboratory’s finding on the role of VEGFA in the ovary 
        Recently, our laboratory published some findings about the role of VEGFA in the 
ovary. We demonstrated that VEGFA and KDR were expressed in pregranulosa and 
granulosa cells of all follicle stages and in theca cells of advanced-stage follicles. Rat 
ovaries treated with VEGFA receptor signal transduction inhibitor had a 94% reduction 
in vessel density. And these ovaries had more primordial follicles, fewer early primary, 
transitional, and secondary follicles, and greater total follicle numbers compared with 
control ovaries. The results indicated that VEGFA is involved in primordial follicle 
activation, maturation and survival (McFee et al., 2009). Another study showed that rat 
ovaries treated with VEGFA164 or VEGFAxxxB antibody had vascular development 
increased by 93%. VEGFA164 treated ovaries had fewer primordial follicles and more 
developing follicles than controls. Ovaries treated with VEGFAxxxB antibody had fewer 
primordial and earlier primary follicles and more primary, transitional, and secondary 
follicles compared with controls. The data suggested that VEGFA proangiogenic isoform 
promotes follicular development (Artac et al., 2009). 
The role of VEGFA in the testis 
        Overexpression of VEGFA164 in the testis and epididymis of transgenic mice 
resulted in upregulation of VEGFA receptors in the endothelial cells, certain 
spermatogenic cells and the Leydig cells and caused infertility. The VEGFA164 
overexpression in testis and epididymis resulted in spermatogenic arrest. This indicated 
that VEGFA may regulate male fertility (Korpelainen et al., 1998). One study on male 
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roe deer showed the strength of VEGFA angiogenic isoforms mRNA expression is 
dependent on the season. It reached its highest level at the peak of spermatogenesis 
during the pre-rutting period and had its nadir at the end of the rut when involution 
already began. These results suggest that VEGFA angiogenic isoforms may directly 
affect the regulation of spermatogenesis (Wagener et al., 2010).  
Our laboratory’s finding on the role of VEGFA in the testis 
        Our laboratory has demonstrated that VEGFA is critical for both vascular 
development and testicular cord formation. Both Treatment with Je-11 (a VEGFA 
antagonists) and VEGFR-TKI (a VEGFA receptor signal transduction inhibitor) 
perturbed cord formation and inhibited vascular density in rat cultured testis. Rat E13 
testes were treated with a phosphoinositide 3-kinase (PI3K) pathway inhibitor which 
resulted in inhibition of both vascular density and cord formation. These studies suggest 
that VEGFA potentially works through the PI3K pathway to promote testicular cord 
formation and vascular density during testis morphogenesis (Bott et al. 2006). Treatment 
of E13 mouse organ culture testes with VEGFA angiogenic isoform or an antibody to 
antiangiogenic isoforms (anti-VEGFAxxxB) resulted in less organized and poorer 
seminiferous cords compared with controls. In addition, VEGFA angiogenic isoform and 
anti-VEGFAxxxB also increased the vasculature density in the mouse culture testes. The 
results from these studies suggest that an imbalance in the production of VEGFA pro- 
versus anti-angiogenic isoforms may impair testis morphology and development. Both 
VEGFA angiogenic and inhibitory isoforms are important for development of vasculature 
and seminiferous cords in rat testes (Baltes-Breitwisch et al., 2010). Recently, we 
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demonstrated that KDR was expressed in germ cells E16, E17, P4, and after P20 in 
mouse testis. KDR-LacZ testis organ cultures treated with VEGFR-TKI had reduced 
numbers of KDR-LacZ stained cell in developing testes; this indicates decreased 
migration of KDR-expressing endothelial cells from the mesonephros to the testis. Thus, 
the VEGFA signal transduction inhibitor reduced the endothelial cell migration during 
testis formation (Bott et al., 2010). Taken together, these studies suggest that VEGFA 
and its receptor are involved in the development of vasculature and seminiferous cords in 
both rat and mouse testes.  
Conclusion 
        Vascular endothelial growth factor is one of the key factors regulating angiogenesis 
in the ovary. It has been demonstrated to be a potential regulator of follicle development 
and ovulation (Kaczmarek et al., 2005; Danforth et al., 2003). Since VEGFA is produced 
in numerous ovarian compartments and its important role in ovarian vascular physiology, 
we hypothesized that production of VEGFA by granulosa cell is critical for normal ovary 
morphogenesis and function. The objective of my first project is to determine the in vivo 
effects of granulosa-cell specific VEGF loss on ovary function and morphogenesis. 
        Besides the role in ovary, VEGFA also plays a critical role in testis development. 
VEGFA and its receptor KDR are present during testis morphogenesis. It has been 
demonstrated that VEGFA is involved in the development of vasculature and 
seminiferous cords in rodent testes and supports germ cell survival (Bott et al., 2006, 
Caires et al., 2009; Baltes-Breitwisch et al., 2010). We hypothesized that VEGFA, 
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produced by Sertoli cells, plays an important role in testis morphogenesis and function. 
The objective of my second project is to determine the in vivo effects of Sertoli cell-
specific VEGFA loss on male reproductive organs’ function and morphogenesis.  
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                                 stage 1:         stage 2:           stage 3:         stage 4:         stage 5: 
                                      Urogenital ridge  Indifferent gonad  Sex determination  Cord formation  Development                                              
                                                                                                                                                          of functional testis 
Fig.1 Morphology stages that occur during testis differentiation from genital ridge 
formation to cord formation and cell proliferation in the mouse with stage in number of 
tail somites (ts) and dpc (figure adapted from Cupp and Skinner, 2005) 
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Fig.2 Model of Opposed Signals in Mammalian Sex Determination (figure adapted from 
DiNapoli and Capelm, 2008) 
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Fig.3 Major stages of mammalian folliculogenesis (figure adapted from Edson et al., 
2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    28 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
.4
 P
ro
te
in
 a
n
d
 m
R
N
A
 p
ro
d
u
ct
s 
o
f 
h
u
m
an
 V
E
G
F
-A
 f
o
ll
ic
u
lo
g
en
es
is
 (
fi
g
u
re
 
ad
ap
te
d
 f
ro
m
 H
ar
p
er
 a
n
d
 B
at
es
, 
2
0
0
8
).
 
 
    29 
 
 
 
 
 
 
 
 
 
F
ig
.5
 S
ig
n
al
li
n
g
 p
at
h
w
ay
s 
d
o
w
n
st
re
am
 o
f 
v
as
cu
la
r 
en
d
o
th
el
ia
l 
g
ro
w
th
 V
E
G
F
A
 
an
g
io
g
en
ic
 a
n
d
 i
n
h
ib
it
o
ry
 i
so
fo
rm
s 
(f
ig
u
re
 a
d
ap
te
d
 f
ro
m
 H
ar
p
er
 a
n
d
 B
at
es
, 
2
0
0
8
) 
 
    30 
 
Literature Cited 
 
Aman A, Piotrowski T. Cell migration during morphogenesis. Dev Biol. 2010. 341:20-33.  
Artac RA, McFee RM, Smith RA, Baltes-Breitwisch MM, Clopton DT, Cupp AS. 
Neutralization of vascular endothelial growth factor antiangiogenic isoforms is more 
effective than treatment with proangiogenic isoforms in stimulating vascular 
development and follicle progression in the perinatal rat ovary. Biol Reprod. 2009. 
81:978-988.  
Autiero M, Waltenberger J, Communi D, Kranz A, Moons L,Lambrechts D, Kroll J, 
Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, 
Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, 
Dehio C, Hicklin DJ, Persico G, Herbert JM, Shibuya M, Collen D, Conway EM, 
Carmeliet P. Role of PlGF in the intra- and intermolecular cross talk between the 
VEGF receptors Flt1 and Flk1. Nat Med. 2003. 9:936–943. 
Baltes-Breitwisch MM, Artac RA, Bott RC, McFee RM, Kerl JG, Clopton DT, Cupp AS. 
Neutralization of vascular endothelial growth factor antiangiogenic isoforms or 
administration of proangiogenic isoforms stimulates vascular development in the rat 
testis. Reproduction. 2010. 140:319-329. 
Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, 
Harper SJ. VEGF165b, an inhibitory splice variant of vascular endothelial growth 
factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002. 62:4123-4131. 
Beardsley A, O’Donnell L. Characterization of normal spermiation and spermiation 
failure induced by hormone suppression in adult rats. Biol Reprod. 2003. 68:1299-
1307.  
Bendel-Stenzel M, Anderson R, Heasman J, Wylie C. The origin and migration of 
primordial germ cells in the mouse. Semin Cell Dev Biol. 1998. 9(4):393-400. 
Boitani C, Politi MG, Menna T. Spermatogonial cell proliferation in organ culture of 
immature rat testis. Biol Reprod. 1993. 48:761–767. 
Bott RC, McFee RM, Clopton DT, Toombs C, Cupp AS. Vascular endothelial growth 
factor and kinase domain region receptor are involved in both seminiferous cord 
formation and vascular development during testis morphogenesis in the rat. Biol 
Reprod. 2006. 75:56-67. 
Bott RC, Clopton DT, Cupp AS. A proposed role for VEGF isoforms in sex-specific 
vasculature development in the gonad. Reprod Domest Anim. 2008. 43 Suppl 2:310-
316.  
Bott RC, Clopton DT, Fuller AM, McFee RM, Lu N, McFee RM, Cupp AS. KDR-LacZ-
expressing cells are involved in ovarian and testis-specific vascular development, 
suggesting a role for VEGFA in the regulation of this vasculature. Cell Tissue Res. 
2010. 342:117–130. 
Brennan J, Karl J, Capel B. Divergent vascular mechanisms downstream of Sry establish 
the arterial system in the XY gonad. Dev Biol. 2002. 244:418-428. 
Bristol-Gould SK, Kreeger PK, Selkirk CG, Kilen SM, Cook RW, Kipp JL, Shea LD, 
Mayo KE, Woodruff TK. Postnatal regulation of germ cells by activin: the 
establishment of the initial follicle pool. Dev Biol. 2006. 298:132-148. 
    31 
 
Buehr M, Gu S, McLaren A. Mesonephric contribution to testis differentiation in the fetal 
mouse. Development. 1993. 117:273-281. 
Buzzard JJ, Wreford NG, Morrison JR. Thyroid hormone, retinoic acid, and testosterone 
suppress proliferation and induce markers of differentiation in cultured rat Sertoli 
cells. Endocrinology. 144:3722–3731. 
Caires KC, de Avila J, McLean DJ. Vascular endothelial growth factor regulates germ 
cell survival during establishment of spermatogenesis in the bovine testis. 
Reproduction. 2009. 138:667-677. 
Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA. Suppression of ovarian 
follicle activation in mice by the transcription factor Foxo3a. Science. 2003. 301:215-
218. 
Chang C, Chen YT, Yeh SD, Xu Q, Wang RS, Guillou F, Lardy H, Yeh S. Infertility 
with defective spermatogenesis and hypotestosteronemia in male mice lacking the 
androgen receptor in Sertoli cells. Proc Natl Acad Sci U S A.  2004. 101:6876–6881. 
Choi Y, Yuan D, Rajkovic A. Germ cell-specific transcriptional regulator sohlh2 is 
essential for early mouse folliculogenesis and oocyte-specific gene expression. 2008. 
Biol Reprod 79:1176–1182. 
Chun SY, Eisenhauer KM, Minami S, Billig H, Perlas E, Hsueh AJ. Hormonal regulation 
of apoptosis in early antral follicles: follicle-stimulating hormone as a major survival 
factor. Endocrinology. 1996. 137:1447–1456. 
Clermont Y. Kinetics of spermatogenesis in mammals: seminiferous epithelium cycle and 
spermatogonial renewal. Physiol Rev. 1972. 52:198–236. 
Colvin JS, Green RP, Schmahl J, Capel B, Ornitz DM. Male-to-female sex reversal in 
mice lacking fibroblast growth factor 9. Cell. 2001. 104:875–889. 
Cui S, Ross A, Stallings N, Parker KL, Capel B, Quaggin SE. Disrupted gonadogenesis 
and male-to-female sex reversal in Pod1 knockout mice. Development. 2004. 
131:4095-105. 
Cupp AS, Uzumcu M, Skinner MK. Chemotactic role of neurotropin 3 in the embryonic 
testis that facilitates male sex determination. Biol Reprod. 2003. 68: 2033–2037. 
Cupp A, Skinner M. Embryonic Sertoli cell differentiation. in: Griswold M, Skinner M 
(eds), Sertoli Cell Biology, Vol. 1. Elsevier Academic Press, San Diego. 2005. pp. 
43–70. 
Danforth DR, Arbogast LK, Ghosh S, Dickerman A, Rofagha R, Friedman CI. Vascular 
endothelial growth factor stimulates preantral follicle growth in the rat ovary. Biol 
Reprod. 2003. 68:1736–1741. 
De Felici M, Pesce M. Growth factors in mouse primordial germ cell migration and 
proliferation. Prog Growth Factor Res. 1994. 5:135-43. 
De Felici M, Farini D, Dolci S. In or out stemness: comparing growth factor signalling in 
mouse embryonic stem cells and primordial germ cells. Curr Stem Cell Res Ther. 
2009. 4:87-97.  
De Gendt K, Swinnen JV, Saunders PT, Schoonjans L, Dewerchin M, Devos A, Tan K, 
Atanassova N, Claessens F, Lécureuil C, Heyns W, Carmeliet P, Guillou F, Sharpe 
RM, Verhoeven G. A Sertoli cell-selective knockout of the androgen receptor causes 
spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A. 2004. 101:1327-1332.  
    32 
 
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like 
tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992. 
255:989–991. 
DiNapoli L, Capel B. SRY and the standoff in sex determination. Mol Endocrinol. 2008. 
22:1-9. 
Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N, Matzuk MM. Growth 
differentiation factor-9 is required during early ovarian folliculogenesis. Nature. 1996. 
383: 531–535. 
Dube JL, Wang P, Elvin J, Lyons KM, Celeste AJ, Matzuk MM. The bone 
morphogenetic protein 15 gene is X-linked and expressed in oocytes. Mol Endocrinol 
1998. 12: 1809–1817. 
Edson MA, Nagaraja AK, Matzuk MM. The mammalian ovary from genesis to revelation. 
Endocr Rev. 2009. 30:624-712. 
Eicher EM, Shown EP, Washburn LL: Sex reversal in C57BL/6JYPOS mice corrected by 
a Sry transgene. Phil Trans R Soc Lond. 1995. 350:263-269. 
Elvin JA, Clark AT, Wang P, Wolfman NM, Matzuk MM. Paracrine actions of growth 
differentiation factor-9 in the mammalian ovary. Mol Endocrinol. 1999. 13:1035–
1048. 
Eppig JJ, Wigglesworth K, Pendola FL. The mammalian oocyte orchestrates the rate of 
ovarian follicular development. Proc Natl Acad Sci U S A. 2002. 99:2890-2894. 
Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth 
factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989. 
161:851-858. 
Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial 
growth factor family of polypeptides.  J Cell Biochem. 1991. 47:211-218. 
Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. 
Endocrine Rev. 2004. 25:581-611. 
Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr 
Rev. 1997. 18:4-25.  
Funke S, Flach E, Kiss I, Sándor J, Vida G, Bódis J, Ertl T. Male reproductive tract 
abnormalities: More common after assisted reproduction Early Hum Dev. 2010. 
86:547-550. 
Geva E, Jaffe RB Role of vascular endothelial growth factor in ovarian physiology and 
pathology. Fertil Steril. 2000. ;74:429-438. 
Grobstein C. Inductive epitheliomesenchymal interaction in cultured organ rudiments of 
the mouse. Science. 1953. 118:52-55. 
Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson RS. Isoforms of vascular 
endothelial growth factor act in a coordinate fashion To recruit and expand tumor 
vasculature. Mol Cell Biol. 2000. 20:7282-7291. 
Hao J, Yamamoto M, Richardson TE, Chapman KM, Denard BS, Hammer RE, Zhao GQ, 
Hamra FK. Sohlh2 knockout mice are male-sterile because of degeneration of 
differentiating typeA spermatogonia. Stem Cells. 2008. 26:1587–1597. 
Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev 
Cancer. 2008. 8:880-887. 
    33 
 
Haywood M, Spaliviero J, Jimemez M, King NJ, Handelsman DJ, Allan CM. Sertoli and 
germ cell development in hypogonadal (hpg) mice expressing transgenic follicle-
stimulating hormone alone or in combination with testosterone. Endocrinology. 2003. 
144:509–517. 
Hirshfield AN. Development of follicles in the mammalian ovary. Int Rev Cytol. 1991a. 
124:43-101. 
Hirshfield AN. Theca cells may be present at the outset of follicular growth. Biol Reprod.  
1991b. 44:1157–1162. 
Holdcraft RW, Braun RE. Hormonal regulation of spermatogenesis. Int J Androl. 2004. 
27:335-342. 
Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial 
growth factor family: identification of a fourth molecular species and characterization 
of alternative splicing of RNA. Mol Endocrinol. 1991. 5:1806–1814. 
Huckins C. The spermatogonial stem cell population in adult rats. I. Their morphology, 
proliferation and maturation. Anat Rec. 1971. 169:533-557. 
Iijima K, Jiang JY, Shimizu T, Sasada H, Sato E. Acceleration of follicular development 
by administration of vascular endothelial growth factor in cycling female rats. J 
Reprod Dev. 2005. 51:161-168.  
Leridon H, Slama R. The impact of a decline in fecundity and of pregnancy 
postponement on final number of children and demand for assisted reproduction 
technology.  Hum Reprod. 2008. 23:1312-1319. 
Kaczmarek MM, Schams D, Ziecik AJ. Role of vascular endothelial growth factor in 
ovarian physiology—an overview. Reprod. Biol. 2005. 5:111–136. 
Karl J, Capel B. Sertoli cells of the mouse testis originate from the coelomic epithelium. 
Dev Biol. 1998. 203:323-333. 
Koopman P, Gubbay J, Vivian N, Goodfellow P, Lovell-Badge R: Male development of 
chromosomally female mice transgenic for Sry. Nature. 1991. 351:117-121. 
Korpelainen E, Karkkainen M, Tenhunen A, Lakso M, Rauvala H, Vierula M, Parvinen 
M, Alitalo K. Overexpression of VEGF in testis and epididymis causes infertility in 
transgenic mice: evidence for nonendothelial targets for VEGF. 1998. J Cell Biol 143; 
1705–1712. 
Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R. WT-
1 is required for early kidney development. Cell. 1993. 74:679-691. 
Kumar TR, Wang Y, Lu N, Matzuk MM. Follicle stimulating hormone is required for 
ovarian follicle maturation but not male fertility. Nat Genet.1997. 15:201–204. 
Kunwar PS, Siekhaus DE, Lehmann R. In vivo migration: a germ cell perspective. Annu 
Rev Cell Dev Biol. 2006. 22:237-265. 
Landgren E, Schiller P, Cao Y, Claesson-Welsh L. Placenta growth factor stimulates 
MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial 
cells expressing Flt1. Oncogene. 1998. 16:359–367. 
Magoffin DA. Ovarian theca cell. Int J Biochem Cell Biol. 2005. 37:1344-1349. 
Magre S, Jost A. Sertoli cells and testicular differentiation in the rat fetus. J Electron 
Microsc Tech. 1991. 19:172–188. 
    34 
 
Mattioli M, Barbara B, Turriani M, Galeati G, Zannoni A, Castellani G,  Berardinelli P, 
Scapolo PA. Follicle activation involves vascular endothelial growth factor 
production and increased blood vessel extension. Biol Reprod. 2001. 65:1014–1019. 
Martineau J, Nordqvist K, Tilmann C, Lovell-Badge R, Capel B. Male-specific cell 
migration into the developing gonad. Curr Biol. 1997. 7:958–968. 
Maru Y, Yamaguchi S, Shibuya M. Flt-1, a receptor for vascular endothelial growth 
factor, has transforming and morphogenic potentials. Oncogene. 1998. 16:2585–2595. 
McFee RM, Artac RA, McFee RM, Clopton DT, Longfellow Smith RA, Rozell. TG, 
Cupp AS.  Inhibition of vascular endothelial growth factor receptor signal 
transduction blocks follicle progression but does not necessarily disrupt vascular 
development in perinatal rat ovaries. Biol Reprod. 2009. 81: 966–977. 
McLachlan RI, O’Donnell L, Meachem SJ, Stanton PG, de Kretser DM, Pratis K, 
Robertson DM. Identification of specific sites of hormonal regulation in 
spermatogenesis in rats, monkeys, and man. Recent Prog Horm Res. 2002. 57:149-
179.  
Merchant-Larios H, Moreno-Mendoza N, Buehr M. The role of the mesonephros in cell 
differentiation and morphogenesis of the mouse fetal testis. Int J Dev Biol. 1993. 
37:407-415. 
Miyamoto N, Yoshida M, Kuratani S, Matsuo I, Aizawa S. Defects of urogenital 
development in mice lacking Emx2. Development. 1997. 124:1653-1664. 
Molyneaux K, Wylie C. Primordial germ cell migration. Int. J. Dev. Biol. 2004. 48:537–
544. 
Nagy JA, Dvorak AM, Dvorak HF. VEGF-A(164/165) and PlGF: roles in angiogenesis 
and arteriogenesis. Trends Cardiovasc Med. 2003. 13:169-175. 
Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, 
Ladomery MR, Harper SJ, Bates DO. Expression of pro- and anti-angiogenic 
isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell 
Sci. 2008.121:3487-3495. 
Oakberg EF. Spermatogonial stem-cell renewal in the mouse. Anat Rec. 1971. 169:515-
531. 
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in 
control of vascular function. Nat Rev Mol Cell Biol. 2006. 7:359-371. 
Pangas SA, Choi Y, Ballow DJ, Zhao Y, Westphal H, Matzuk MM, Rajkovic A. 
Oogenesis requires germ cell-specific transcriptional regulators Sohlh1 and Lhx8. 
Proc Natl Acad Sci USA. 2006. 103:8090–8095. 
Pepling ME, Spradling AC. Female mouse germ cells form synchronously dividing cysts. 
Development. 1998. 125:3323-3328. 
Pepling ME, Spradling AC. Mouse ovarian germ cell cysts undergo programmed 
breakdown to form primordial follicles. Dev Biol. 2001. 234:339-351. 
Phillips BT, Gassei K, Orwig KE. Spermatogonial stem cell regulation and 
spermatogenesis. Philos Trans R Soc Lond B Biol Sci. 2010. 365:1663-1678. 
Phillips HS, Hains J, Leung DW, Ferrara N. Vascular endothelial growth factor is 
expressed in rat corpus luteum. Endocrinology. 1990. 127:965–967. 
    35 
 
Rajkovic A, Pangas SA, Ballow D, SuzumoriN, Matzuk MM. NOBOX deficiency 
disrupts early folliculogenesis and oocyte-specific gene expression. Science. 2004. 
305:1157–1159. 
Ravindranath N, Little-Ihrig L, Phillips HS, Ferrara N, Zeleznik AJ. Vascular endothelial 
growth factor messenger ribonucleic acid expression in the primate ovary. 
Endocrinology. 1992. 131:254–260. 
Ricci G, Catizone A, Innocenzi A, Galdieri M. Hepatocyte growth factor (HGF) receptor 
expression and role of HGF during embryonic mouse testis development. Dev Biol. 
1999. 216: 340–347. 
Richards JS. Hormonal control of gene expression in the ovary. Endocr Rev. 1994. 
15:725–751. 
Richards JS. Ovulation: new factors that prepare the oocyte for fertilization. Mol Cell 
Endocrinol. 2005. 234:75-79. 
Roberts AE, Arbogast LK, Friedman CI, Cohn DE, Kaumaya PT, Danforth DR. 
Neutralization of endogenous vascular endothelial growth factor depletes primordial 
follicles in the mouse ovary. Biol Reprod. 2007. 76:218–223. 
Ruwanpura SM, McLachlan RI, Stanton PG, Meachem SJ. Follicle-stimulating hormone 
affects spermatogonial survival by regulating the intrinsic apoptotic pathway in adult 
rats. Biol Reprod. 2008a 78:705–713. 
Ruwanpura SM, McLachlan RI, Stanton PG, Loveland KL, Meachem SJ. Pathways 
involved in testicular germ cell apoptosis in immature rats after FSH suppression. J 
Endocrinol. 2008b. 197:35–43. 
Ruwanpura SM, McLachlan RI, Meachem SJ. Hormonal regulation of male germ cell 
development. J Endocrinol. 2010. 205:117-123. 
Schmahl J, Eicher EM, Washburn LL, Capel B. Sry induces cell proliferation in the 
mouse gonad. Development. 2000. 127:65-73.  
Schmahl J, Capel B. Cell proliferation is necessary for the determination of male fate in 
the gonad. Dev Biol. 2003. 258:264-276.  
Sharpe RM, McKinnell C, Kivlin C, Fisher JS. Proliferation and functional maturation of 
Sertoli cells, and their relevance to disorders of testis function in adulthood. 
Reproduction. 2003. 125:769-784. 
Shawlot W, Behringer RR. Requirement for Lim1 in head-organizer function. Nature. 
1995. 374:425-430. 
Shu X, Wu W, Mosteller RD, Broek D. Sphingosine kinase mediates vascular endothelial 
growth factorinduced activation of ras and mitogen-activated protein kinases. Mol 
Cell Biol. 2002. 22:7758–7768. 
Skakkebaek NE, Jørgensen N. Testicular dysgenesis and fertility. Andrologia. 2005. 
37:217-218. 
Skinner MK. Regulation of primordial follicle assembly and development. Hum Reprod 
Update. 2005. 11:461-471. 
Skinner MK, Anway MD. Seminiferous cord formation and germ-cell programming: 
epigenetic transgenerational actions of endocrine disruptors. Ann N Y Acad Sci. 2005. 
1061:18-32. 
    36 
 
Solovyeva EV, Hayashi M, Margi K, Barkats C, Klein C, Amsterdam A, Hsueh AJ, 
Tsafriri A. Growth differentiation factor-9 stimulates rat theca-interstitial cell 
androgen biosynthesis. Biol Reprod. 2000. 63:1214-1218. 
Stocco C, Telleria C, Gibori G. The molecular control of corpus luteum formation, 
function, and regression. Endocr Rev. 2007. 28:117-149. 
Swain A, Lovell-Badge R. Mammalian sex determination: a molecular drama. Genes Dev. 
1999. 13:755-767. 
Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial 
growth factors. Cardiovasc Res. 2005. 65:550-563. 
Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. 
The human gene for vascular endothelial growth factor. Multiple protein forms are 
encoded through alternative exon splicing. J Biol Chem. 1991. 266:11947–11954. 
Tripathi R, Mishra DP, Shaha C. Male germ cell development: turning on the apoptotic 
pathways. J Reprod Immunol. 2009. 83:31-35. 
Uzumcu M, Dirks KA, Skinner MK. Inhibition of platelet-derived growth factor actions 
in the embryonic testis influences normal cord development and morphology. Biol 
Reprod. 2002 Mar;66(3):745-53. 
Vihko KK, LaPolt PS, Nishimori K, Hsueh AJ. Stimulatory effects of recombinant 
follicle-stimulating hormone on Leydig cell function and spermatogenesis in 
immature hypophysectomized rats. Endocrinology. 1991. 129:1926–1932. 
Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial 
growth factor gene to human chromosome 6p21.3. Circulation. 1996. 93:1493–1495. 
Wagener A, Blottner S, Göritz F, Streich WJ, Fickel J. Circannual changes in the 
expression of vascular endothelial growth factor in the testis of roe deer (Capreolus 
capreolus). Anim Reprod Sci. 2010. 117:275-278. 
Walker WH, Cheng J. FSH and testosterone signaling in Sertoli cells. Reproduction. 
2005. 130:15-28. 
Waltenberger J, Claesson Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal 
transduction properties of KDR and Flt1, two receptors for vascular endothelial 
growth factor. J Biol Chem. 1994. 269:26988–26995. 
Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, 
Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, 
Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO. VEGF165b, an inhibitory 
vascular endothelial growth factor splice variant: mechanism of action, in vivo effect 
on angiogenesis and endogenous protein expression. Cancer Res. 2004. 64:7822-7835. 
Yang MY, Fortune JE. Vascular endothelial growth factor stimulates the primary to 
secondary follicle transition in bovine in vitro. Mol Reprod Dev. 2007. 74:1095-1104. 
Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular 
endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-
2-mediated endothelial cell proliferation, but not migration, through 
phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem. 2001. 276: 26969–
26979. 
Zimmermann RC, Xiao E, Husami N, Sauer MV, Lobo R, Kitajewski J, Ferin M: Short-
term administration of antivascular endothelial growth factor antibody in the late 
    37 
 
follicular phase delays follicular development in the rhesus monkey. J Clin 
Endocrinol Metab. 2001. 86:768-772. 
 Zimmermann RC, Xiao E, Bohlen P, Ferin M: Administration of antivascular endothelial 
growth factor receptor 2 antibody in the early follicular phase delays follicular 
selection and development in the rhesus monkey. Endocrinology. 2002. 143:2496-
2502. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    38 
 
Chapter 2 
Granulosa cell-specific Vascular Endothelial Growth Factor A (VEGFA) loss using 
pDMRT-1 Cre alters ovarian morphogenesis, reduces plasma estrogen 
concentrations and impairs fertility 
Abstract 
        VEGFA is a critical regulator of vascular physiology in the ovary and plays an 
important role in the regulation of follicular growth. The objective of the current study 
was to evaluate effects of granulosa cell-specific production of VEGFA isoforms on the 
vascular development and ovarian morphogenesis. The pDmrt1 gene is expressed in the 
indifferent gonad in precursor granulosa and Sertoli cells and in some specific germ cell 
lineages. We used a pDmrt1-cre mouse crossed to a floxed VEGFA mouse to determine 
potential phenotypes in female granulosa-cell (VEGFA-DGranG) specific knockouts. 
Ovaries, uterus, kidneys and adrenals were collected from adult mice, and weighed 
(control n=11, VEGFA-DGranG n=10). The weight of ovaries from VEGFA-DGranG 
was significantly smaller than that of the control (0.0144+0.0014 VS 0.0183+0.0009 g, P 
< 0.05). Ovaries from VEGFA-DGranG had reduced numbers of CL/ovary than the 
control (2.25+0.4119 VS 4+0.4629, P < 0.05) and two of those VEGFA-DGranG females 
had abnormal CL morphology. Serum estradiol concentrations in the VEGFA-DGranG 
mice were 55% of control mice (48.83+9.58 VS 89.48+13.17 pg/ml, P < 0.05). The 
number of days mated until parturition was 12 days longer in VEGFA-DGranG X 
VEGFA-DSertG pairs versus control females mated with control males (38.27+4.65 VS 
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26.18+2.17 days, P < 0.05). Therefore, we conclude from these data that absence of both 
VEGFA pro-angiogenic and anti-angiogenic isoforms may alter ovarian morphogenesis, 
follicle development and ovulation resulting in impaired fertility in female mice. 
Introduction 
        In mammals, female reproductive life span depends not only on the size of the 
primordial follicle pool, but also on the complement of follicles and development of those 
follicles during the peripubertal period. Abnormalities in either primordial follicle pool 
development or follicle progression may result in impairment of ovarian function 
(Mazaud et al., 2002). There is intense angiogenesis and increased permeability of blood 
vessels during follicular development, ovulation and formation of the corpus luteum. The 
availability of an adequate vascular supply to provide endocrine and paracrine signals 
have been shown to play a key role in the regulation of follicle growth (Redmer and 
Reynolds, 1996). Angiogenesis plays an important role in follicular development with 
independent regulation of vasculature within each follicle contributing to its development 
(Fraser, 2006). VEGFA is one of the key factors regulating angiogenesis in the ovary. 
VEGFA stimulates neovascularization, vascular permeability, acts as a survival factor 
and can also stimulates proliferation of vascular and nonvascular cells. 
        Several studies have demonstrated that VEGFA is important in the growth of 
capillary vessels around follicles in the ovary and it also promotes development of 
ovarian follicles in rats and mice (Shimizu et al., 2003; Kaczmarek et al., 2005; Danforth 
et al., 2003; Quintana et al., 2004), including both preantral and antral follicular 
    40 
 
development (Shimizu et al., 2007; Danforth et al., 2003). VEGFA production is critical 
in the control of follicle growth and activity (Mattioli et al., 2001). Kosaka et al. reported 
that VEGFA inhibited bovine granulosa cell apoptosis. These results demonstrated that 
VEGFA not only acts in vascular formation but also functions as a survival factor for 
ovarian follicles (Kosaka et al., 2007).  
        In addition to development of the vasculature and apoptosis, VEGFA also appears to 
regulate ovulation. In vivo studies showed that inhibition of VEGFA and VEGF receptor-
2 can inhibit follicular development or prevent ovulation (Zimmermann et al., 2001; 
Zimmermann et al., 2002). Furthermore, injection of a VEGFA antagonist into the pre-
ovulatory follicle in rhesus monkey resulted in half of the animals failing to ovulate with 
the large follicles of these females becoming luteinized (Zimmermann et al., 2002). Thus, 
in addition to follicular development VEGFA also appears to affect ovulation. 
        The Vegf family comprises five members, including Vegfa, Vegfb, Vegfc, Vegfd 
(officially called Figf, c-fos-induced growth factor) and placenta growth factor (Pgf). The 
significant one of Vegf family is Vegfa in the ovary. The Vegfa gene has eight exons and 
can be alternatively spliced by different factors to produce angiogenic or inhibitory 
isoforms. VEGFA angiogenic or inhibitory isoforms have opposite functions (angiogenic 
isoforms promote vascular development while anti-angiogenic isoforms inhibit vascular 
development). To initiate biological effects, VEGFA binds two related tyrosine kinase 
receptors: FMS-like tyrosine kinase 1 (FLT1, also known as VEGFR1) and kinase insert 
domain receptor (KDR, also known as VEGFR2 and FLK1). The primary receptor is 
KDR (Ferrara et al., 2003).  KDR is the major mediator of the mitogenic, angiogenic and 
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permeability enhancing effects of VEGFA. KDR is involved in mediating endothelial cell 
proliferation, survival and vascular permeability, whereas FLT1 might play an inhibitory 
role by sequestering VEGFA, and preventing its interaction with KDR (Ferrara et al., 
2004). Roberts et al. reported ovarian administration of antibodies to KDR resulted in 
significant depletion of primordial follicle numbers, whereas anti-FLT1 antibodies did 
not (Roberts et al., 2007). This is consistent with KDR receptor as the primary mediator 
of VEGFA action in the ovary and that the FLT1 receptor might be a decoy for VEGFA.  
    In the human ovary, VEGFA is produced by the theca and granulosa cells 
(Yamamoto et al., 1997; Roberts et al., 2007). Our laboratory has demonstrated that 
VEGFA and its receptors are also localized to pre-granulosa and granulosa cells of all 
follicle stages and to theca cells of advanced-stage follicles in rat (McFee et al., 2009). 
An in situ study showed the in vivo expression of VEGFA in different cell types 
including theca, cumulus, granulosa and luteal cells in mouse ovary (Shweiki et al., 
1993). Independent of its angiogenic effects, VEGFA may also be important in the 
regulation of follicle growth with direct effects on granulosa cells. Rat ovaries treated 
with VEGFA receptor-tyrosine kinase inhibitor had vascular development reduced by 94% 
and follicle progression was blocked since there were more primordial follicles, and 
fewer early primary, transitional, and secondary follicles compared to controls. This 
study demonstrated a novel role for VEGFA in the recruitment of primordial follicles into 
the growing follicle pool, as well as a potential survival factor for primary and later-stage 
follicles through vascular dependent and vascular-independent mechanisms (McFee et al., 
2009). Further studies from our laboratory demonstrated that treatments with both 
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neutralization of anti-angiogenic VEGFA isoforms and pro-angiogenic isoform VEGFA 
164 enhanced vascular and follicular development in perinatal rat ovaries. These results 
suggest that VEGFA isoforms are involved in vascular development and follicle 
activation in the rat ovary with pro-angiogenic isoforms stimulating follicle progression 
and anti-angiogenic isoforms inhibiting or arresting follicle development (Artac et al., 
2009).  
        Thus, VEGFA is an important regulator of ovarian vascular physiology and is 
produced in numerous ovarian compartments. In the current study, we hypothesized that 
production of VEGFA isoforms (both pro and anti-angiogenic) by granulosa cells is 
critical for normal ovary morphogenesis and function. Therefore, the objective of present 
study was to determine the in vivo effects of granulosa-cell specific VEGFA loss on 
ovary function and morphogenesis.  
Materials and methods 
Animals    
        Granulosa cell-specific VEGFA KO mice were obtained by using the Cre-loxP 
approach. We used a line of VEGFA
loxp/loxp
 mice (Gerber et al., 1999) from Napoleon 
Ferrara at Genentech to mate with pig Dmrt1-cre mice (Boyer et al., 2002) to develop 
granulosa and Sertoli cell-specific VEGFA knockout mice (breeding scheme in Appendix 
A). The Dmrt1 gene is expressed in the indifferent gonad at 10.5 dpc in precursor cells 
that differentiate into Sertoli and granulosa cells. By 12.5 dpc, Dmrt1 is expressed in 
Sertoli cells and germ cells in XY gonads and in ovarian somatic cells and germ cells. 
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Dmrt1 is evident in Sertoli cells at all ages examined and absent in ovarian somatic cells 
from 13.5 dpc. Expression of Dmrt1 in primordial germ cells increases through 13.5 dpc 
and absent by 15.5 dpc. Sexual differences in germ cell Dmrt1 were detected after birth, 
when it was detected only in spermatogonia of the testis (Lei et al., 2007). The pDmrt1 
gene is expressed similar to mouse Dmrt1 (Boyer et al., 2002). In our VEGFA-DGranG 
mouse, VEGFA gene exon 3 was flanked by two loxp sites and Cre, driven by pig Dmrt1, 
bound and deleted the DNA sequence between the two flox. The VEGFA was not 
expressed in the cells where Dmrt1 is present. We used Cre-negative VEGFA
loxp/loxp 
or 
VEGFA
loxp/+
 mice as controls and Cre-positive VEGFA
loxp/loxp 
mice as KO (VEGFA-
DGranG). Ovaries, uterus, kidneys and adrenals were collected from female adult mice 
that were cycling, non-pregnant and were at random stage of the estrous cycle  (control 
n=11, VEGFA-DGranG n=10) and weighed. All the female were approximately 250 days 
of age. All animal protocols were approved by the University of Nebraska Institute of 
Animal Care and Use Committee (IACUC) in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. 
Genotyping: 
        DNA was extracted from tail samples and used for genotyping via polymerase chain 
reaction (primers and PCR programs are listed in Appendix B). Genomic DNA was 
extracted from tails of mice by proteinase K digestion and followed by 6M NaCl 
extraction and ethanol precipitation (Bott et al., 2010).  
 
    44 
 
Embedding, Histology and staining (hemotoxylin and eosin staing; H&E): 
        Ovaries were fixed in Bouin’s solution and rinsed in 70% ethanol. Embedding was 
performed according to the standard procedures (McFee et al., 2009; Bott et al., 2010).  
Prior to paraffin embedding, ovaries were rinsed in 100% ethanol 1 hour for 3 times and 
CitriSolve (Fisher Scientific, Fairlawn, IL) 1 hour for 3 times. Embedded tissues were 
sectioned (5 µm) and the slides were placed in an incubator (37
°
C) overnight. Sectioned 
ovaries were deparaffinized, stained with hematoxylin for 1 min (VWR International, 
West Chester, PA) and eosin for 30 min (Ricca, Arlington, TX), dehydrated and mounted. 
Immunohistochemistry: 
        Sectioned tissues were deparaffinized, rehydrated, and microwaved in 0.01 M 
sodium citrate to boil for 15 min. Then, tissues were cooled for 1 h and rinsed in 3% 
hydrogen peroxide in methanol for 20 min. Sections were blocked with 10% normal goat 
serum in PBS for 30 min at room temperature and washed in PBS 3 times. 
Immunohistochemistry was performed according to the standard protocol in our 
laboratory (Mcfee et al., 2009). The Cyp11a1 primary antibody (catalog number: 
ab78416; Abcam, Cambridge, Mass., USA) was diluted in 1:200 in 10% normal goat 
serum.  As a negative control, serial sections were processed without primary antibody. 
Biotinylated goat anti-rabbit secondary antibodies were diluted 1:300. Secondary 
antibody was detected using aminoethyl carbazole (AEC) chromagen substrate solution 
(ZYMED Laboratories, SanFrancisco, CA). Sections were counterstained with 
hematoxylin to determine cell types that were stained with respective antibodies. 
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RNA isolation: 
        Total RNA from ovaries was extracted using Tri-Reagent according to 
manufacturer’s protocol (Sigma, St. Louis, MO). After isolation total RNA was dissolved 
in 20 µl diethyl pyrocarbonate (DEPC) water. The extracted RNA was diluted 1:14 in 
DEPC water and the concentration was determined by spectroscopy at 260nm using the 
Lambda EZ 150 (Perkin Elmer). 
Reverse Transcription (RT)-PCR: 
        Before RT-PCR, 1 µl of RNA was removed from each sample to a new tube with 15 
µl DEPC water to be used as ―No RT‖ to detect the residual genomic DNA. RT was 
performed on 5 µg of template using SuperScript II (Invitrogen, Carlsbad, CA) according 
to the manufacturer’s recommended protocol (McFee et al., 2009; Bott et al., 2010). RT 
samples were incubated in 65
°
C with 2 µl of oligo (dT) 15 primer (Promega), 2 µl 
dexoxynucleotide triphosphates (Fermantas; 10 mM dNTP mix), 3.8 µl DEPC water, and 
then immediately chilled on the ice. After that, 1 µl SuperScript II reverse transcriptase 
(200 units/µl; Invitrogen, Carlsbad, CA), 3.2 µl of stand buffer (Invitrogen, Carlsbad, 
CA), 2 µl 0.1 M DL-dithiothreitol (DTT) (Invitrogen, Carlsbad, CA), 1 µl DEPC water 
were added into each sample. The samples were incubated at 42
°
C for 1 hour followed by 
15 min at 70
°
C to inactivate the reverse transcriptase. The cDNA was stored at 20
°
C for 
subsequent real time-PCR. 
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Quantitative RT- PCR (QRT-PCR): 
    Quantitative real-time PCR primers and probes used in the experiment were shown 
in table 1. Glyceradehyde-3-phosphate dehydrogenase (Gapdh) gene is a housekeeping 
gene and used as a control for RNA amplification. QRT-PCR was performed in 364 well 
plates (Axygen Scientific, Union City, CA) with an adhesive cover film (VWR, Scientific 
Products, North Kansas City, MO). Gapdh, Bcl-2 and Bax were performed with 10 µl 
Taqman universal Master Mix (Applied Biosystem, Foster City, CA), 1 µl cDNA, 0.5 µl 
of each forward and reverse primers, 2 µl probe, and 6 µl DEPC to make up the reaction 
volume to 20 µl. Foxo3a, Gdnf-9, Cyp17a1 and Cyp11a1 were performed with 10 µl 
SYBR Green PCR Master Mix (Applied Biosystem, Foster City, CA), 1 µl cDNA, 0.6 µl 
of each forward and reverse primers, and 7.8 µl DEPC to make up the reaction volume to 
20 µl. Experimental and Gapdh PCRs were carried out in separate wells in triplicate. An 
arbitrary value of template was assigned to the highest standard and corresponding values 
were assigned to the subsequent dilutions. These relative values are plotted against the 
threshold value for each dilution to generate a standard curve. The relative amount for 
each experimental and Gapdh triplicate was assigned an arbitrary value based on the 
slope and y-intercept of the standard curve. The average of the experimental triplicate is 
divided by the average of the Gapdh triplicate, and the resulting normalized values are 
used for statistical analysis (McFee et al. 2009).  
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Blood collection and Hormone Enzyme-Linked Immunosorbent Assay (ELISA): 
        Blood was collected at the time of euthanization and put into tubes with 20 µl EDTA 
solution (Fisher Scientific Co., Fair Lawn, NJ). Blood sample was immediately 
centrifuged at 1250 X g for 10 mins, the plasma was removed into a new tube and stored 
in -80
°
C. Estradiol level was determined by Estradiol ELISA kit (Alpha Diagnostics 
International Inc., San Antonio, TX; Cat. No.1920). Samples remained undiluted and 
were run according to the manufacture’s direction. Standard curve samples were made of 
10 pg, 50 pg and 150 pg to ensure that all samples were on the curve. Assay sensitivity 
was 10 pg/ml. The progesterone concentration was determined by Progesterone ELISA 
kit (Alpha Diagnostics International Inc., San Antonio, TX; Cat. No. 1860). Standard 
curve samples were made of 0.5 ng/ml, 1 ng/ml, 5 ng/ml, 10 ng/ml, 30 ng/ml. Assay 
sensitivity was 0.2 ng/ml. Testosterone concentration was determined by Testosterone 
ELISA kit (Alpha Diagnostics International Inc., San Antonio, TX; Cat. No.1880). 
Standard curve samples were made of 0 ng/ml, 0.5 ng/ml, 1 ng/ml, 2.5 ng/ml, 10 ng/ml 
and 20 ng/ml. Assay sensitivity was 0.125 ng/ml. 
Statistical analysis: 
        All data were analyzed by two-sample t-test using SAS software (SAS institute, 
Cary, NC). Differences in data were considered statistically significant at P < 0.05. 
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Results 
Phenotypes in the female ovary of VEGFA-DGranG mice: 
         The ovarian weight and morphology were used to evaluate the effect of granulosa 
cell-specific VEGFA loss on female ovary. As shown in figure 2A, the weight of ovaries 
was significantly decreased for VEGFA-DGranG females compared with the controls 
(0.0144+0.0014 VS 0.0183+0.0009 g, P < 0.05). To assess the effect of granulosa cell-
specific VEGFA loss on ovary histological morphology, ovaries were stained by H&E. 
VEGFA-DGranG mice had ovaries with fewer antral follicles and corpus lutea (CL), and 
two VEGFA-DGranG mice had abnormal morphology in structures that appeared to be 
CL (fig. 1). To examine the effect of granulosa cell-specific VEGFA loss on ovulation, 
we counted the number of CL in the ovary. Cyp11a1 was used as a marker to count 
numbers of CL/ovary (fig. 3A, B, C). As shown in figure 3D, the number of CL/ovary 
from VEGFA-DGranG mice was significantly less than that from control mice 
(2.25+0.4119 VS 4+0.4629, P < 0.05). These results indicated that there were reduced 
ovulation rate potentially caused by reductions in production of antral follicles on the 
ovary of VEGFA-DGranG mice. 
Effect of Granulosa cell-specific VEGFA loss on female mouse uterus, kidneys and 
adrenals: 
        To test whether Granulosa cell-specific VEGFA loss affects other organs in the 
mouse, we compared the weight of those organs between VEGFA-DGranG and control 
females. There were no significant differences on the weight of uterus (0.1094+0.0094 
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VS 0.1036+0.0103 g, P =0 .68, fig. 2B), kidneys (0.3782+0.0157 VS 0.4231+0.0208 g, P 
= 0.13, fig. 2C) or adrenals (0.0082+0.0007 VS 0.0087+0.0005 g, P = 0.54, fig. 2D) 
between VEGFA-DGranG mice and control mice. So only ovarian weight was affected 
by granulosa cell specific VEGFA loss. 
Effect of Granulosa cell-specific VEGFA loss on 17 beta estradiol, progesterone, and 
testosterone concentrations: 
        Blood collected was used to measure circulating hormone levels. Serum 17β-
estradiol concentrations in the VEGFA-DGranG females were 55% of those in controls 
(48.83+9.58 VS 89.48+13.17 pg/ml, P < 0.05, fig. 4A). There was no significant 
difference in progesterone concentrations between the VEGFA-DGranG and control 
females (145.49+31.81 VS 135.39+15.66 ng/ml, P = 0.78, fig 4B). Serum testosterone 
was not significantly different between the VEGFA-DGranG mice and control mice 
(0.12+0.02 VS 0.16+0.02 ng/ml, P = 0.26, fig 4C).  
Effect of Granulosa cell-specific VEGFA loss on gene expression in ovary: 
        Because one study demonstrated that injection of a VEGFA inhibitor to prepubertal 
eCG treated rats significantly increased the levels of Bax and decreased the levels of Bcl-
2 protein content of antral follicle (Abramovich et al., 2006). We evaluated the effect of 
Bcl-2 and Bax mRNA expression in Granulosa cell VEGFA loss within the ovary. Bcl-2 
and Bax mRNA in VEGFA-DGranG were not significant different from control (Bcl-2: 
6.51+2.27 VS 11.07+4.50, P = 0.53, fig. 5A; Bax: 5.76+2.57 VS 4.41+1.10, P = 0.56, fig. 
5B). In addition, there was no difference in ratio of Bcl-2 to Bax (3.36+2.60 VS 
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87.84+73.10, P = 0.28, fig. 5C). But Bcl-2 averages were 2 fold higher in controls versus 
VEGFA-DGranG KO’s and the ratios of Bcl-2 to Bax was 26 fold higher in controls. 
Thus, variation in our control’s severely affected our ability to detect differences in this 
gene and gene ratio. Forkhead boxo3a (Foxo3a) is a transcription factor and arrests 
follicle progression. Foxo3a mRNA was not significantly different between VEGFA-
DGranG ovary and control (8.80+3.62 VS 4.99+1.24, P = 0.23, fig. 5D). Nor was an 
oocyte marker, growth differentiation factor (Gdf-9) (Sun et al., 2010) mRNA different 
between VEGFA-DGranG ovary and control (148.91+59.89 VS 223.45+70.99, P = 0.53, 
fig. 5E). Cyp11a1 converts cholesterol to pregnenolone and Cyp17a1 converts 
pregnenolone to androgen. As shown in figure 5F and 5G, Cyp17a1 (3851.28+3079.76 
VS 1340.91+ 436.37, P = 0.48) and Cyp11a1 (82,659.33+37,082.03 VS 
8,509,574.76+8,420,312.39, P = 0.48) mRNA in the ovary between VEGFA-DGranG 
and control was not statistically significant different. Cyp11a1 mRNA in VEGFA-
DGranG ovary is 103 fold higher in controls; but the variation in control’s Cyp11a1 gene 
expression and reduced numbers of KOs inhibited our ability to detect differences in this 
gene.  
Effect of Granulosa cell-specific VEGFA loss on fertility: 
        To determine whether Granulosa cell-specific VEGFA loss has any effect on 
fertility, VEGFA-DGranG females were mated with males that had VEGFA knocked out 
in Sertoli and some germ cells (VEGFA-DSertG). There were 5 KO groups and 9 control 
groups. We found that the number of days for VEGFA-DGranG females mating with 
VEGFA-DSertG males until parturition was (12 days) longer than that for control 
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females mating with control males (38.27+4.65 VS 26.18+2.17 days, P < 0.05, fig. 6). 
This indicated that the rate of ovulation in female mice or sperm quantity in the males 
may be affected by VEGFA-specific granulosa and Sertoli knock outs. There was no 
significant difference in number of litters/female in approximate 2 months, pups/litter 
between VEGFA-DGranG females with VEGFA-DSertG males group and control 
females with control males group (2.20+0.37 VS 1.67+0.24 litter numbers/female in  
approximate 2 months, P = 0.23; 8.18+0.74 VS 7.64+0.40 pups/litter, P = 0.50).  
Discussion 
        In the current study, we determined that VEGFA loss in granulosa cells increased 
the time from mating to parturition, reduced number of antral follicles, numbers of 
CL/ovary and reduced estrogen concentrations by 55%. Thus, these females were 
subfertile due to the loss of both angiogenic and anti-angiogenic VEGFA isoforms. The 
reduction in fertility may be due to less overall follicle progression and maturation, 
reduced ovulations, or through reduced production of estrogen. The reduction in follicle 
maturation is supported by the smaller ovarian weight and reduction in estrogen 
concentrations in blood; suggesting that less follicles reached the antral stage where 
estrogen production is maximal.   
        The formation of a dense capillary network (angiogenesis) in the ovary enables the 
hormone-producing cells to obtain the oxygen, nutrients and also precursors necessary to 
synthesize and release different hormones essential for maintenance of the ovarian 
functions (Kaczmarek et al., 2005). Loss of VEGFA in granulosa cells may reduce 
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angiogenesis, the blood supply for oxygen, nutrients and influence the growth of the 
ovary and follicle maturation. The reduction in ovarian weight in the VEGFA-DGranG 
females may be due to a decline in maturation of follicles and this is also supported by 
the dramatic reduction in estrogen that was present in these females. 
        Follicles are surrounded by somatic cells (granulosa and theca cells) and can be 
classified into preantral (primordial, primary and secondary) and antral (tertiary and 
preovulatory) follicles. Quiescent primordial follicles and slow growing preantral 
follicles do not have a vascular supply of their own, but instead rely on vessels in the 
surrounding stroma (Brunol et al., 2009). Stromal blood vessels transport nutrients and 
oxygen to primordial and primary follicles through passive diffusion. Follicular growth is 
associated with the development of an individual capillary network and continued 
angiogenesis to nourish the rapidly expanding follicle. Some types of infertility may be 
associated with the disturbance of follicular angiogenesis, which results in inadequate 
development (Fraser, 2006). Acquisition of an adequate vascular supply is probably a 
limiting step in the selection and maturation of the dominant follicle destined to ovulate 
(Stouffer et al., 2001). 
        Our lab also demonstrated that VEGFA is involved in primordial follicle activation, 
maturation and survival (McFee et al., 2009). Rat ovaries treated with VEGFA_164 or 
VEGFAxxxB antibody had a 93% increase in vascular density. VEGFA_164 treated 
ovaries were composed of fewer primordial follicles (stage 0) and more developing 
follicles (stages1–4) than controls. Ovaries treated with VEGFAxxxB antibody had fewer 
primordial and early primary follicles and more primary, transitional, and secondary 
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follicles compared to controls. These data suggested that VEGFA proangiogenic isoform 
promote follicle development, and in constrast, VEGFA anti-angiogenic isoforms 
maintain primordial follicles in an arrested state. Removal of VEGF anti-angiogenic 
isoforms allows for increased progression of primordial follicles to the developing 
follicle pool (Artac et al., 2009). VEGFA also promotes the primary into secondary 
follicle transition in bovine follicles activated in vitro stimulating follicular growth in 
cattle (Yang and Fortune et al., 2007) as well as rodents.  
In our study, ovarian weight in VEGFA-DGranG mice was smaller than that of 
control. This suggests granulosa cell-specific VEGFA loss within mouse ovary does 
affect ovarian size through reduction of follicle development and/or maturation. In 
previous studies direct injection of VEGFA in the rat ovary increased the number of 
antral follicles and promoted the development of antral follicles by inducing the 
formation of theca vasculature. The results of VEGFA treatment were increased cross-
sectional area of ovaries with VEGFA injection compared to controls (Shimizu et al., 
2007). Another reason for the reduced ovarian size in the VEGFA-DGranG females is 
due to the reduced CL and potentially a decrease in ovulation rate. An in vivo study 
showed that the VEGFA angiogenic isoform promoted ovarian follicular angiogenesis 
leading to stimulatory effects on subsequent follicular development and numbers of 
oocytes ovulated in mature cycling rats (Iijima et al., 2005). Inhibition of VEGFA and 
KDR suppress follicular development and ovulation (Zimmermann et al., 2001; 
Zimmermann et al., 2002). The fewer CL in VEGFA-DGranG may be caused by fewer 
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antral follicles and less ovulation in those mice. Even though CL numbers were reduced 
there was no significant difference in progesterone concentrations in the serum. 
        Our previous data showed that rat ovaries treated with VEGFA 164 or VEGFAxxxB 
antibody increased the vascular density (Artac et al., 2009). In newly formed CL, 
VEGFA mRNA and protein expression are observed in the granulosa- and theca-derived 
luteal cells. In several species, expression levels are higher in granulosa-derived cells 
than that in theca-derived luteal cells (Kamat et al., 1995; Endo et al., 2001; 
Boonyaprakob et al., 2003; Kaczmarek et al., 2005). Highly expressed VEGFA in 
granulosa-derived luteal cells may act as a chemoattractant for endothelial cells in order 
to initiate the invasion of avascular granulosa layer establishing an extensive capillary 
network that nourishes the development of CL and assists in the maintenance of luteal 
function throughout its’ lifespan (Kaczmarek et al., 2005). In the present study, two 
ovaries of VEGFA-DGranG mice showed abnormal morphological structure in CL which 
appeared to be devoid of vasculature. It is possible that granulosa cell-specific VEGFA 
loss affects the establishment of capillary network in developing CL and consequently 
influences the structure of CL. 
        Estrogens are produced primarily by developing follicles in the ovary (Yang et al., 
2000). Other tissues such as the liver, adrenal glands, and the breast also produce 
estrogens in a smaller amount. Granulosa cells in the ovary can convert androstenedione 
to estrone or estradiol. The aromatase knockout mouse, the estrogen β receptor knockout 
mouse, and the estrogen α receptor knockout mouse have demonstrated that estrogen 
enhances the number of follicles progressing to the early antral stage (Fisher et al., 1998; 
    55 
 
Krege et al., 1998; Schomberg et al., 1999; Danforth et al., 2003). Furthermore, a 
positive relationship between VEGFA and E2 concentrations in the gilt follicular fluid 
suggest a possible cause-and-effect relationship (Mattioli et al., 2001) with VEGF 
stimulating estrogen production by increasing vascular permability to cholesterol and 
increasing signal transduction pathways activating enzymes that are critical to estrogen 
production. One study showed that serum 17β-estradiol concentration in rats treated with 
VEGFA120 and 164 were significantly higher than that in the control rats, indicating that 
VEGFA120 and 164 may indirectly stimulate the production of 17β-estradiol via 
granulosa cells (Iijima et al., 2005). In our study, serum 17β-estradiol level in the 
VEGFA-DGranG was significantly lower than that in the control. Our results indicated 
that loss of VEGFA in granulosa cell may inhibit the production of 17β-estradiol via 
granulosa cells in the mouse.  
        VEGFA suppresses apoptosis in vascular endothelial cells by regulating Bcl-2 
family proteins (Gerber et al., 1998; Nör et al., 1999). The members of this family consist 
of anti-apoptotic factors (such as Bcl-2 and Bcl-xL) and pro-apoptotic factors (such as 
Bax). Bcl-2 maintains permeability of the mitochondrial membrane. However, Bax 
increases permeability of the mitochondrial membrane and stimulates apoptosis inducers 
(such as cytochrome C and Smac/Diablo) which were released from mitochondria into 
the cytosol. The mitochondrial apoptotic inducers in the cytosol stimulate the activation 
of the caspase cascade. Activated caspase cascades can result in apoptosis. VEGFA is a 
key survival factor for endothelial cells and induces the expression of Bcl-2 in human 
endothelial cell (Gerber et al., 1998). Local inhibition of VEGFA activity appeared to 
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produce an increase in ovarian apoptosis through an imbalance among the follicular 
contents of Bcl-2 family members’ protein, thus leading a larger number of atretic 
follicles (Abramovich et al., 2006). 
        However, VEGFA does not stimulate or inhibit Bcl-xL and Bax, respectively, in 
bovine Granulosa cells. It is hypothesized that VEGFA does not suppress the expression 
of active caspase-3. VEGFA suppresses granulosa cell apoptosis by suppressing the 
downstream activities of caspase-3 without being associated with the mitochondrial 
pathway. Because VEGFA has tyrosine kinase receptors, it may act via Akt or Erk in the 
downstream cascade of caspase-3 to inhibit granulosa cell apoptosis (Kosaka et al., 2007). 
The exact mechanism of how VEGFA acts on the granulosa cell or follicular survival still 
needs to be elucidated. Besides Bcl-2 and Bax, we also determined expression of other 
genes in the ovary.  
        Foxo3a is a key oocyte factor critical for suppressing primordial follicle activation 
(Castrillon et al., 2009). Foxo3a mRNA is 1.76 fold higher in KO’s ovary than control. 
Although, the difference is not significant, the higher value in KO may suggest follicle 
progression is suppressed in these ovaries. Gdf-9, produced by oocyte, plays critical roles 
in early follicular development. This oocyte-derived paracrine factor also stimulates 
follicular somatic cell proliferation and steroidogenesis (Elvin et al., 1999). There is no 
statistical significant difference on Gdf-9 mRNA between the KO’s ovary and controls. 
However, the mRNA average is 34% lower in VEGFA-DGranG ovary. Thus, less Gdf-9 
expression may inhibit follicular development, somatic cell proliferation and estrogen 
synthesis. We did not have enough tissue to evaluate protein for Bxl-2, Bax, Foxo3a, or 
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Gdf-9. Thus it is also possible that difference in protein production of these genes result 
from VEGFA isoform loss.  
        Our KO mice from the present study were subfertile. The time period from mating 
to parturition in female VEGFA-DGranG mice was 12 days longer compared to the 
control. This suggested a decreased rate of ovulation in the female VEGFA-DGranG 
mice or ovulation of oocytes that are not competent to ovulate. Ha et al., suggest that 
estrogen administration improves number and quality of oocytes which may possibly be 
mediated by the increase of ovarian VEGF expression. In our study, reduced estrogen 
may reduce the number and quality of oocytes and VEGFA expression in the ovary. 
Furthermore, VEGFA loss in granulosa cells may diminish the number of healthy 
preovulatory follicles and ovulated oocytes.  
        Follicular vascularization appears to have a critical influence on the development of 
competing human oocytes and early embryos. Follicular vascularity and oxygen content 
appear to be important factors of oocyte competence (Van. 1998). In an in vivo 
experiment, Iijima et al. treated mature female rats with VEGFA120 or 164 and an 
angiogenic inhibitor (TNP-470) during the estrous cycle. They reported that VEGFA 
angiogenic treatment stimulated follicular angiogenesis, while TNP-470 treatment 
showed severe depression of follicular angiogenesis and completely inhibited ovulation. 
After treatment with VEGFA 120 and 164, the number of healthy preovulatory follicles 
and ovulated oocytes significantly increased and the number of atretic preovulatory 
follicles decreased (Iijima et al., 2005). In Iijima’s experiment, the oocytes ovulated had 
a normal ability to fertilize and develop to term with the same litter size as in the control 
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rats. In the current study, to determine the quality of the oocytes ovulated by granulosa 
cell-specific VEGFA loss, VEGFA-DGranG mice were mated with VEGFA-DSertG 
mice and allowed to proceed to pregnancy. The number of litters/female in approximate 
two months or pups/litter was not significantly different between the VEGFA-specific 
knockout mice and controls. However the time to produce a litter was longer in our 
knockout matings suggesting that there may be multiple problems in obtaining viable 
embryos that are capable of being maintained for a complete pregnancy. Thus, granulosa 
cell-specific VEGFA loss may have effects on embryo viability.          
        In conclusion, we demonstrated that removal of VEGFA in granulosa cells within 
ovaries resulted in reduced ovarian weight, fewer CL and reduced estrogen 
concentrations (by 55%). Furthermore, the time period between mating and parturition is 
longer in female VEGFA-DGranG KO’s than that in controls. The present data suggest 
that VEGFA is necessary for normal follicular development, ovulation rate, estrogen 
concentration and timing of mating to parturition and without VEGFA angiogenic and 
antiangiogenic isoforms females are subfertile. 
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Figure Legends 
 
Table 1. Quantitative Real-time PCR primers, probes and kit. 
 
Figure 1. Effect of granulosa cell-specific VEGFA loss on morphology of ovary. 
Histological images of sections (H&E stained) of control ovaries (A, C, E) and VEGFA-
DGranG ovaries (B, D, F, G). Two VEGFA-DGran ovaries had abnormal morphology in 
structures that appeared to be CL (F, G).  
 
Figure 2. Effect of granulosa cell-specific VEGFA loss on ovaries (A) uterus (B), 
kidneys (C) and adrenals (D) in female mouse. The mean weights + SEM are presented. * 
denotes significant difference at P < 0.05. 
 
Figure 3. Cyp11a1 immunohistochemistry (IHC) images (A, B, C) and effect of 
granulosa cell-specific VEGFA loss on the numbers of Corpus Lutea (D). A is showing 
the H&E stained CL, B is showing Cyp11a1 IHC stained CL (brown color), and C is the 
negative control for IHC. The mean numbers of CL per ovary + SEM are presented. * 
denotes significant difference at P < 0.05.  
 
Figure 4. Effect of granulosa cell-specific VEGFA loss on the serum E2 (A), 
progesterone (B) and testosterone (C) concentrations. The mean serum concentrations + 
SEM are presented. * denotes significant difference at P < 0.05. 
 
Figure 5. Effect of granulosa cell-specific VEGFA loss on Bcl-2 (A), Bax (B), Bcl-2/Bax 
(C), Foxo3a (D), Gdf-9 (E), Cyp17a1 (F) and Cyp11a1 (G) mRNA expression in the 
ovary. The mean normalized values + SEM are presented. 
 
Figure 6. Time from mating control female with control male to parturition VS time 
from mating VEGFA-DGranG females with VEGFA-DSertG males to parturition. There 
were 5 KO groups and 9 control groups. The mean days from mating to parturition + 
SEM are presented. * denotes significant difference at P < 0.05.  
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Gene Forward Primer Probe 
Dye 
Probe 
Vendor 
Reverse Primer 
Gapdh Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems Catalog #4308313 
(VIC Probe) 
Bcl-2 CGTTGGCCCTTCGGAGTT FAM Applied 
Biosystems 
TCAGACCTCCAGGGCAGAGA 
Bax GGCCTTTTTGCTACAGGGT
TT 
FAM Applied 
Biosystems 
GTGTCTCCCCAGCCATCCT 
Foxo3a GCAAAGCAGACCCTCAAA
CTG 
SYBR 
Green 
Applied 
Biosystems 
TGAGAGCAGATTTGGCAAAGG 
Gdf-9 GCCGGGCAAGTACAGCC SYBR 
Green 
Applied 
Biosystems 
TTTGTAAGCGATGGAGCCG 
Cyp17a1 
 
TGGAAGGATGCACAGGTT
GA 
SYBR 
Green 
Applied 
Biosystems 
ATGGGATCCGGGACGTTAG 
Cyp11a1 CCCCCTGGGTGGCCTAT SYBR 
Green 
Applied 
Biosystems 
TGAACTCTTAAACAGGACCCCA
AT 
 
 
 
 
 
 
 
Table 1. 
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Chapter 3 
Sertoli cell-specific Vascular Endothelial Growth Factor A (VEGFA) loss using 
pDMRT-1 Cre reduces testis size, increases testosterone, and affects genes involved in 
the apoptotic pathway resulting in subfertile males 
Abstract: 
        VEGFA is present during testis morphogenesis and is expressed by Sertoli cells and 
germ cells. Inhibition of VEGFA disrupts both testis-specific vascular development and 
cord formation. We hypothesize that production of VEGFA isoforms by Sertoli cells is 
critical for normal testis morphogenesis. Therefore, the objective of the current study was 
to evaluate the effects of Sertoli cell-specific production of VEGFA isoforms on sex-
specific vascular development and gonadal morphogenesis. The pDmrt1 gene is 
expressed in the indifferent gonad in precursor Sertoli and granulosa cells and in some 
sub-populations of germ cells. Therefore, we used a pDMRT1-cre crossed to a floxed 
VEGFA mouse to generate male Sertoli-cell (VEGFA-DSertG) specific knockouts. 
Reproductive organs were collected from adult mice, and weighed (control n=9, VEGFA-
DSertG n=8). Testosterone concentrations in blood were determined by ELISA. In 
VEGFA-DSertG males, the body weight (28.52+0.48 VS 32.52+1.20 g); testes 
(0.1658+0.0064 VS 0.1924+0.0061 g) and epididymal (0.0627+0.0046 VS 
0.0792+0.0042 g) weight were significantly reduced compared to controls (P < 0.05). 
The prostate weight in VEGFA-DSertG males also tended to be smaller than controls 
(0.0104+0.0031 VS 0.0215+0.0044 g, P = 0.06). Morphologically the epididymis and 
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prostate were different with fewer tubules and sperm in the epididymis and reduced 
branching in the prostate compared to controls. Serum testosterone levels in VEGFA-
DSertG males tended to be higher than those in controls (5.28+2.24 VS 0.97+0.33 ng/ml, 
P = 0.097). Three VEGFA-DSertG males had 10 fold greater testosterone concentrations 
than controls (12.81 VS 0.97 ng/ml). Relative amounts of Bcl-2 mRNA in VEGFA-
DSertG testes tended to be greater than that in controls (4.51+1.26 VS 1.89+0.27, P = 
0.07). The ratio of Bcl-2/Bax tended to be increased in VEGFA-DSertG testes compared 
to control (1.20+0.33 VS 0.54+0.08, P = 0.08). Relative amounts of Bax (3.71+0.52 VS 
4.10+0.53, P = 0.67), Sin3a (34.17+9.97 VS 18.72+2.90, P = 0.17) and aromatase 
(10.77+2.3 VS 9.01+1.77, P = 0.56) mRNA in VEGFA-DSertG testes were not 
significantly different compared to control. But Sin3a mRNA in three VEGFA-DSertG 
males with high testosterone concentration was significantly higher than controls 
(42.08+13.91 VS 18.72+2.90, P = 0.01). Therefore, we can conclude from these data that 
lack of VEGFA in Sertoli cells (and sub-populations of germ cells) reduces gonadal and 
male accessory gland organ weights, alters steroidogenic profiles and Bcl-2 and Sin3a 
expression in testis. Thus, VEGFA plays an important role in male reproductive organ 
morphogenesis and function in mice.  
Introduction 
        Human fertility rates have declined all over the world. Currently, increased human 
infertility suggests that significant reproductive health problems exist (Skakkebaek et al., 
2005) and this is why they have identified a new disorder- testicular dysgenesis syndrome 
(TDS). Male reproductive health disorders, including impaired semen quality, testicular 
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cancer, cryptorchidism and hypospadias are all associated with testicular dysgenesis 
syndrome which is thought to occur due to abnormal embryonic or fetal development of 
cells involved in testis differentiation and morphogenesis (Joensen et al., 2009).  
        Testis development is initiated by Sertoli cell differentiation and expression of Sry, 
causing mesonephric cell migration into the differentiating testis to form seminiferous 
cords (Cupp and Skinner 2005). Seminiferous cord formation and sex-specific vascular 
formation are only present in the testis and therefore are first to distinguish morphology 
in the indifferent gonad. Vascular endothelial growth factor A (VEGFA) is a paracrine 
growth factor responsible for blood vessel development as well as endothelial cell 
migration. Expression of VEGFA in normal testes, prostate and seminal vesicles and 
semen suggests that VEGFA could play a role in male reproductive physiology 
(Huminiecki et al., 2001; Obermair et al., 1999).  
        The Vegf family includes Vegfa, Vegfb, Vegfc, Vegfd (officially called Figf, c-fos-
induced growth factor) and placenta growth factor (Pgf). The predominant gene in Vegf 
family is Vegfa. The Vegfa gene is composed of eight exons and by different factors 
produces angiogenic or inhibitory isoforms. These two isoforms have opposite functions 
(angiogenic isoforms promote vasculature development while anti-angiogenic isoforms 
inhibit vascular development). Two related tyrosine kinases receptors, FMS-like tyrosine 
kinase 1(FLT1, also known as VEGFR1) and kinase insertion domain receptor (KDR, 
also known as VEGFR2 and FLK-1), bind to VEGFA. The primary receptor involved in 
the action of VEGFA is KDR (Ferrara et al., 2003). KDR is the major mediator of the 
mitogenic, angiogenic and permeability effects of VEGFA. It has been demonstrated that 
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KDR participate in mediating endothelial cell proliferation, survival and vascular 
permeability, whereas FLT1 might play an inhibitory role by sequestering VEGFA, and 
preventing its interaction with KDR (Ferrara et al., 2004).  
       VEGFA and its receptor KDR are detected at the time of testis morphogenesis. 
VEGFA is expressed by Sertoli cells and other cells within the seminiferous cords in 
early development (Bott et al., 2006). FLT1 and KDR were expressed by both Leydig 
cells and germ cell of the testis (Korpelainen et al., 1998; Bott et al., 2006; Bott et al., 
2010). It has been demonstrated that overexpression of VEGFA in the testis and 
epididymis of transgenic mice leads to upregulation of VEGFA receptors in the 
endothelial cells, in certain spermatogenic cells and the Leydig cells, and causes 
infertility. The VEGFA overexpression in testis and epididymis exhibited spermatogenic 
arrest and the ductus epididymidis was dilated, containing areas of epithelial hyperplasia 
in mice (Korpelainen et al., 1998). In the previous studies, our laboratory demonstrated 
that VEGFA, a Sertoli cell secreted growth factor, is critical for both vascular 
development and cord formation. Treatment with VEGFA antagonists or VEGFA 
receptor signal transduction inhibitors arrested cord formation and reduced vascular 
density in organ cultures of rat testes (Bott et al. 2006). Treatment of E13 cultured mouse 
testes with VEGFA angiogenic isoform or an antibody to antiangiogenic isoforms (anti-
VEGFAxxxB) resulted in undefined and poorly developed seminiferous cords compared 
with the cords in control. Moreover, the vasculature density increased in the cultured 
mouse testes with VEGFA angiogenic isoform or an anti-VEGFAxxxB. The results 
suggest that both pro- and antiangiogenic VEGFA isoforms are involved in the 
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development of vasculature and seminiferous cords in rat testes, and differential 
expression of these isoforms may be important for normal gonadal development (Baltes-
Breitwisch et al., 2010). Recently, we also found that KDR-LacZ testis cultured with 
VEGF receptor tyrosine kinase inhibitor (VEGFR-TKI) present reduced endothelial cell 
migration during testis development (Bott et al., 2010). Taken together, these studies 
suggest that VEGFA, secreted by Sertoli cells, is involved in the development of 
vasculature and seminiferous cords in rodent testes. 
        We proposed that VEGFA plays an important role in testis morphogenesis and 
function. To investigate the effects of VEGFA in vivo, we generated Sertoli cell-specific 
VEGFA loss transgenic mice. The objective of present study is to determine the in vivo 
effects of Sertoli cell-specific VEGFA loss on male reproductive organs’ function and 
morphogenesis. 
Materials and methods 
Animals:    
        Sertoli cell-specific VEGFA KO mice were obtained by using the Cre-loxP 
approach. We used a line of VEGFA
loxp/loxp
 mice (Gerber et al., 1999) from Napoleon 
Ferrara at Genentech to mate with pig DMRT1-cre mice (Boyer et al., 2002) to develop 
Sertoli and granulosa cell-specific VEGFA knockout mice (breeding scheme in Appendix 
A). The Dmrt1 gene is expressed in the indifferent mouse gonad at 10.5 dpc in precursor 
cells that differentiate into Sertoli and granulosa cells. By 12.5 dpc, Dmrt1 is expressed in 
Sertoli cells and germ cells within XY gonads and in ovarian somatic cells and germ cells. 
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DMRT1 is presented in Sertoli cells at all ages examined and absent in ovarian somatic 
cells from 13.5 dpc. Expression of Dmrt1 in primordial germ cells increases through 13.5 
dpc and is absent by 15.5 dpc. In germ cell, DMRT1 was detected only in spermatogonia 
of the testis after birth (Lei et al., 2007). The pDmrt1 gene is expressed similar to mouse 
Dmrt1 (Boyer et al., 2002). In our VEGFA-DSertG mouse, VEGFA gene exon 3 was 
flanked by two loxp and Cre, driven by pig Dmrt1, bound and deleted the DNA sequence 
between the two loxp. The VEGFA was not expressed in the cells where Dmrt1 is present. 
Therefore, we expected potential phenotypes in male Sertoli and female granulosa cell 
(and sub-populations of germ cell) knockouts. We used Cre-negative VEGFA
loxp/loxp 
or 
VEGFA
loxp/+
 mice as controls and Cre-positive VEGFA
loxp/loxp 
mice as KO (VEGFA-
DSertG). Testes, epididymis, prostate, seminal vesicles, kidneys and adrenals were 
collected from male adult mice (control n=9, VEGFA-DSertG n=8) and weighed. The 
average age for the KO group was 178 days and for the control group was 175 days. All 
animal protocols were approved by the University of Nebraska Institute of Animal Care 
and Use Committee (IACUC) in accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals. 
Genotyping: 
        DNA was extracted from tail samples and used for genotyping via polymerase chain 
reaction (primers and PCR programs are listed in Appendix B). Genomic DNA was 
extracted from tails of mice by proteinase K digestion and followed by 6M NaCl 
extraction and ethanol precipitation (Bott et al., 2010). 
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Embedding, Histology and staining (hemotoxylin and eosin staing; H&E): 
        Testes, epididymis and prostate were fixed in Bouin’s solution and rinsed in 70% 
ethanol. Embedding was performed according to standard procedures (McFee et al., 2009; 
Bott et al., 2010). Prior to paraffin embedding, tissues were rinsed in 100% ethanol 1 
hour for 3 times and CitriSolve (Fisher Scientific, Fairlawn, IL) 1 hour for 3 times. 
Embedded tissues were sectioned (5 µm) and the slides were placed in an incubator 
(37 
°
C) overnight. Sectioned tissues were deparaffinized, stained with hematoxylin for 1 
min (VWR International, West Chester, PA) and eosin for 30 min (Ricca, Arlington, TX), 
dehydrated and mounted. 
Immunohistochemistry: 
        Sectioned tissues were deparaffinized, rehydrated, and microwaved in 0.01 M 
sodium citrate to boil for 15 min. Then, tissues were cooled for 1 h and rinsed in 3% 
hydrogen peroxide in methanol for 20 min. Sections were blocked with 10% normal goat 
serum in PBS for 30 min at room temperature and washed in PBS 3 times. 
Immunohistochemistry was performed according to the standard protocol in our 
laboratory (Mcfee et al., 2009). DDX4/MVH, a primordial germ cell marker, (catalog 
number: ab13840; Abcam, Cambridge, Mass., USA) was diluted 1:500 in 10% normal 
goat serum. The aromatase primary antibody (catalog number: ab18995; Abcam) was 
diluted in 1:100 in 10% normal goat serum.  As a negative control, serial sections were 
processed without primary antibody. Biotinylated goat anti-rabbit secondary antibodies 
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were diluted 1:300. Secondary antibody was detected using aminoethyl carbazole (AEC) 
chromagen substrate solution (ZYMED Laboratories, San Francisco, CA).  
RNA isolation: 
        Total RNA from testes was extracted using Tri-Reagent according to manufacturer’s 
protocol (Sigma, St. Louis, MO). After isolation total RNA was dissolved in 20 µl diethyl 
pyrocarbonate (DEPC) water. The extracted RNA was diluted 1:14 in DEPC water and 
the concentration was determined by spectroscopy at 260nm using the Lambda EZ 150 
(Perkin Elmer). 
Reverse Transcription (RT)-PCR: 
        Before RT-PCR, 1 µl of RNA was removed from each sample to a new tube with 15 
µl DEPC water to be used as ―No RT‖ to detect the residual genomic DNA. RT was 
performed on 5 µg of template using SuperScript II (Invitrogen, Carlsbad, CA) according 
to the manufacturer’s recommended protocol (McFee et al., 2009; Bott et al., 2010). RT 
samples were incubated in 65
°
C with 2 µl of oligo (dT) 15 primer (Promega), 2 µl 
dexoxynucleotide triphosphates (Fermantas; 10 mM dNTP mix), 3.8 µl DEPC water, and 
then immediately chilled on ice. After that, 1 µl SuperScript II reverse transcriptase (200 
units/ µl; Invitrogen, Carlsbad, CA), 3.2 µl of stand buffer (Invitrogen, Carlsbad, CA), 2 
µl 0.1 M DL-dithiothreitol (DTT) (Invitrogen, Carlsbad, CA), 1 µl DEPC water were 
added into each sample. The samples were incubated at 42
°
C for 1 hour followed by 15 
mins at 70
°
C to inactivate the reverse transcriptase. The cDNA was stored at 20
°
C for 
subsequent real time-PCR. 
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Quantitative RT- PCR (QRT-PCR): 
    Primers, probes and kit used in the experiment were shown in table 1. 
Glyceradehyde-3-phosphate dehydrogenase (Gapdh) gene is a housekeeping gene and 
used as a control for RNA amplification. QRT-PCR was performed in 364 well plates 
(Axygen Scientific, Union City, CA) with an adhesive cover film (VWR, Scientific 
Products, North Kansas City, MO). Bcl-2, Bax and Aromatase were performed with 10 µl 
Taqman universal Master Mix (Applied Biosystem, Foster City, CA), 1 µl cDNA, 0.5 µl 
of each forward and reverse primers, 2 µl probe, and 6 µl DEPC to make up the reaction 
volume to 20 µl. Sin3a were performed with 10 µl Taqman universal Master Mix 
(Applied Biosystem, Foster City, CA), 1 µl cDNA, 1 µl of primers and probe mix 
(Applied Biosystem, Foster City, CA), and 8 µl DEPC to make up the reaction volume to 
20 µl.  Experimental and Gapdh PCRs were carried out in separate wells in triplicate. An 
arbitrary value of template was assigned to the highest standard and corresponding values 
were assigned to the subsequent dilutions. These relative values are plotted against the 
threshold value for each dilution to generate a standard curve. The relative amount for 
each experimental and Gapdh triplicate was assigned an arbitrary value based on the 
slope and y-intercept of the standard curve. The average of the experimental triplicate is 
divided by the average of the Gapdh triplicate, and the resulting normalized values are 
used for statistical analysis (McFee et al. 2009).  
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Blood collection and Hormone Enzyme-Linked Immunosorbent Assay (ELISA): 
        Blood was collected at the time of euthanization and put into tubes with 20 µl EDTA 
solution (Fisher Scientific Co., Fair Lawn, NJ). Blood sample was immediately 
centrifuged at 1250 X g for 10 min; the plasma was removed into a new tube and stored 
in -80
°
C. Testosterone concentration was determined by Testosterone ELISA kit (Alpha 
Diagnostics International Inc., San Antonio, TX; Cat. No.1880). Standard curve samples 
were made of 0 ng/ml, 0.5 ng/ml, 1 ng/ml, 2.5 ng/ml, 10 ng/ml and 20 ng/ml. Assay 
sensitivity was 0.125 ng/ml. 
Statistical analysis: 
        All data were analyzed by two-sample t-test using SAS software (SAS institute, 
Cary, NC). Differences in data were considered statistically significant at P < 0.05 
Results 
Phenotypes in the male testis of VEGFA-DSertG mice: 
        In VEGFA-DSertG, the body and testes weights were significantly smaller than 
those from the control (body: 28.52+0.48 VS 32.52+1.20 g; testes: 0.1658+0.0064 VS 
0.1924+0.0061 g, P < 0.05; fig. 1G and 1H). To assess the effect of Sertoli cell-specific 
VEGFA loss on testes histological morphology, testes were stained with H&E. There was 
no significant difference in morphology of testis (fig. 1A-F).  
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Phenotype of seminal vesicles, kidneys and adrenals in VEGFA-DSertG: 
        In VEGFA-DSertG, seminal vesicles, kidneys and adrenals weight were not 
significantly different compared to those in control (seminal vesicles: 0.2324+0.0134 VS 
0.2579+0.0281 g, P = 0.43; kidneys: 0.4673+0.0122 VS 0.4947+0.0239 g, P = 0.34; 
adrenals: 0.0077+0.0022 VS 0.0068+0.0016 g, P = 0.7). 
Gene expression in testis: 
        Because it is demonstrated that VEGFA angiogenic isoform treatment increased the 
expression of Bcl-2 relative to Bax in bovine testis (Caires et al., 2009). We evaluated 
Bcl-2 and Bax mRNA expression in the testis. As shown in fig. 2A, Bcl-2 in VEGFA-
DSertG tended to be higher than that in control (4.51+1.26 VS 1.89+0.27, P = 0.07). 
Sertoli cell-specific VEGFA loss stimulated production of Bcl-2 mRNA in testis. Bax in 
VEGFA-DSertG was not different from controls (3.71+0.52 VS 4.10+0.53, P = 0.67, fig. 
2B). In addition, Sertoli cell-specific VEGFA loss tended to increase the ratio of Bcl-2 to 
Bax (1.20+0.33 VS 0.54+0.08, P = 0.08, fig. 2C). Swi-independent 3a (Sin3a) is 
specifically expressed in Sertoli cells in the testis and it is required by Sertoli cells to 
establish a niche for undifferentiated spermatogonia and spermatid elongation (Payne et 
al., 2010). Relative amount of Sin3a mRNA was not significant different between 
VEGFA-DSertG testes and control (fig. 2D) (34.17+9.97 VS 18.72+2.90, P = 0.17). 
However, the amount of Sin3a mRNA in those three male KOs with high testosterone 
was significantly higher than the controls (42.08+13.91 VS 18.72+2.90, P = 0.01, fig.2E).  
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Effect of Sertoli cell-specific (and sub-populations of germ cell) VEGFA loss on 
testosterone concentration in serum and aromatase in testis: 
        Blood was collected to test circulating hormone levels. Serum testosterone 
concentration in the VEGFA-DSertG mice tended to be higher than those in control mice 
(5.28+2.24 VS 0.97+0.33 ng/ml, P = 0.097, fig. 3G). The testosterone concentrations in 
three VEGFA-DSertG mice had 10 fold (13.83, 13.72, 10.88 ng/ml) higher 
concentrations compared to controls (0.97+0.33 ng/ml, fig. 3H). Aromatase converts 
testosterone to estrogen in Sertoli cells. We stained for aromatase with 
immunohistochemistry. It is shown that aromatase was expressed in both Leydig cells, 
some germ cells and Sertoli cells. Aromatase positive staining in VEGFA-DSertG was 
not significantly different from that in the control (fig 3A-F). Aromatase mRNA 
(10.77+2.3 VS 9.01+1.77, P = 0.56, fig. 3I) in testis was not significantly different 
between VEGFA-DSertG and controls.  
Effect of Sertoli cell-specific (sub-populations of germ cells) VEGFA loss on germ cell: 
        To examine whether Sertoli cell-specific VEGFA loss alter the germ cell numbers in 
testis, we used immunohistochemistry for VASA (a known germ cell marker) to 
determine if there were differences in germ cell numbers. There was no difference in the 
germ cell number on randomly counted areas of the testis between the VEGFA-DSertG 
and control (fig. 4) as measured with VASA positive staining.  
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Effect of Sertoli cell-specific VEGFA loss on epididymis: 
         Epididymis is part of reproductive tract in the male, which was also observed in the 
current study. Epididymal weight in VEGFA-DSertG was significantly smaller than that 
in control (0.0627+0.0046 VS 0.0792+0.0042 g, P < 0.05, fig. 5G). To evaluate the 
morphology, the epididymis was embedded, sectioned and stained with hematoxylin and 
eosin (H&E). The epididymal head in VEGFA-DSertG appeared to have fewer tubules 
than the control. Besides the reduced numbers of tubules, VEGFA-DSertG epididymis 
also appeared to have fewer sperm in lumen than the controls (fig. 5A-F).  
Effect of Sertoli cell-specific VEGFA loss on prostate: 
        The prostate is an important gland in males. The prostate gland produces, and 
secretes an alkaline fluid which is a part of semen and provides a protective buffer for 
sperm survival in the oviduct. In the present study, the prostate in VEGFA-DSertG males 
also tended to be smaller than controls (0.0104+0.0031 VS 0.0215+0.0044 g, P = 0.06, 
fig. 6G). The VEGFA-DSertG prostate showed less branching and a less differentiated 
morphology than the control (fig. 6A-F).  
Effect of Sertoli cell-specific (sub-populations of germ cells) VEGFA loss on fertility:  
        To determine whether Sertoli cell-specific VEGFA loss has any effect on fertility, 
VEGFA-DSertG mice were mated with females that had VEGFA knocked out in 
granulosa and some germ cells (VEGFA-DGranG). There were 5 KO groups and 9 
control groups. We found that the number of days for VEGFA-DGranG females mating 
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with VEGFA-DSertG males until parturition was longer than that for control females 
mating with control males (38.27+4.65 VS 26.18+2.17 days, P < 0.05, fig. 7).  
Discussion: 
        In the present study, we used Cre-lox technology to knockout VEGFA in Sertoli 
cells and in sub-populations of germ cells. Our goal was to determine how this affected 
morphology and function. We demonstrated that removal of VEGFA in VEGFA-DSertG 
males affected growth since body weight, testis and epididymal weights were smaller 
with tendencies for the prostate to be smaller. Furthermore, Bcl-2 mRNA expression also 
increased in VEGFA-DSertG testis, suggesting that increased cell apoptosis may occur. 
Furthermore, the Sertoli cell-specific VEGFA loss affected the morphology of 
epididymis and prostate resulting in fewer tubules in the epididymis and reduced 
branching in the prostate.  
        VEGFA is a key regulator of endothelial growth and permeability. However, an 
increasing number of reports suggest that VEGFA has direct effects on nonvascular cells 
including granulosa cells (Greenaway et al. 2004) and germ cells (Caires et al., 2009). 
For transgenic mice, losing one of the VEGFA alleles also results in embryonic death 
before testis development in utero (Ferrara et al. 1996). But the role of VEGFA in 
extravascular cells has not yet been understood. We are the first to generate the Sertoli 
cell-specific VEGFA loss mice. Because the VEGFA was conditional knockout, the 
embryonic lethality did not occur. The adult mice were used to observe the effect of 
VEGFA on testis morphology and function.  
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        Since previous studies in our laboratory demonstrated that rat testes treated with 
inhibitors of VEGFA receptors and/or antagonists to VEGFA ligands during sex 
differentiation had decreased vessel density (Bott et al., 2006); we initially proposed that 
elimination of VEGFA in Sertoli cells may affect formation of the testis. This is 
supported by other reports of VEGFA angiogenic isoform overexpression in testis also 
increased capillary density in mice (Korpelainen et al., 1998). These data suggest that 
VEGFA plays an important role in testis development. It may regulate the testis growth 
through regulating vessel density and thus the smaller testis in VEGFA-DSertG may due 
to less vessel density and inability of the testis to grow and develop due to inhibition of 
proliferation and migration of necessary cells from the mesonephros. Our laboratory has 
demonstrated that mesonephric cells expressing KDR appear to migrate into the 
developing testis and surround developing seminiferous cords at E11.5 in the mouse. 
Inhibition of VEGFA signal transduction impaired the migration of endothelial cells in 
cultured gonad. Thus, VEGFA may regulate the endothelial cell migration in gonads 
(Bott et al., 2010). 
        Secondly, we proposed that the reduced size of testis in the VEGFA-DSertG KO 
mice was due to reduced total numbers of germ cells and developing sperm that were 
present within the testis. There is supporting evidence that KDR is expressed in germ 
cells during embryonic period and after birth in the testes suggesting that VEGFA may 
affect differentiation and proliferation of spermatogonia (Bott et al., 2010). In bovine 
testis, VEGFA164 treatment caused more germ cells (Caires et al., 2009). The VEGFA 
overexpression in testis induced spermatogenic arrest and infertility in mice (Korpelainen 
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et al., 1998).  However, when we used VASA staining to determine germ cells numbers 
there was no differences in VEGFA-DSertG males and controls on the randomly counted 
areas of the testis. There does not appear to be any direct effect on germ cell numbers on 
randomly counted areas of the testis. But the total number of germ cell may be altered, so 
overall size of the testis was affected. 
        In the present study, the expression of Bcl-2 and Bcl-2/Bax were increased in 
VEGFA-DSertG testis. One possibility is due to increased germ cell apoptosis signaling 
that mice need more Bcl-2 to prevent the apoptosis. Recombinant mouse VEGFA_164 
treatment increased numbers of germ cells in bovine testes following 5 days of culture 
when compared with controls. Increased expression of Bcl-2 relative to Bax and 
decreased expression of Bnip3 indicated VEGFA_164 also stimulated an intracellular 
response that prevents germ cell death in bovine testis tissue explants. Blocking VEGFA 
activity in vitro reduced the number of germ cells in VEGFA-treated testis tissue (Caires 
et al., 2009). This suggests that VEGFA angiogenic isoform is a survival factor in germ 
cell. Loss of all VEGFA isoforms may result in less germ cells developing and reduced 
spermatogenesis. Increased germ cell apoptosis signaling may stimulate expression of 
Bcl-2 to support germ cell survival and sperm production. Increased amount of Bcl-2 may 
also be compensating for reduced VEGFA angiogenic isoforms. Besides, the higher Bcl-2 
mRNA and Bcl-2/Bax in KOs, the Sin3a mRNA also increased in VEGFA-DSertG testes. 
It is possible like Bcl-2, increased germ cell apoptosis or reduced sperm numbers 
stimulate more Sin3a to support spermatogenesis.  
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        Testosterone concentration in plasma tended to be higher in VEGFA-DSertG mice 
than controls because three VEGF-DSertG males had 10 fold greater testosterone 
concentrations than controls (12.81 vs 0.97 ng/ml). One in vitro study showed that VEGF 
angiogenic isoforms increased testosterone production in mouse TM3 Leydig cells by a 
dose-dependent manner. Administration of anti-VEGF antibody to block the signaling 
through VEGF receptor resulted in an inhibitory effect of testosterone secretion (Hwang 
et al., 2007). However, an ectopic study showed no relationship between VEGF 
angiogenic isoform treatment and serum testosterone concentration. In that study, bovine 
testis tissue was treated with VEGFA_164 before grafting onto castrated 
immunodeficient nude mice. Serum testosterone concentrations in mice with cultured 
testis tissue grafts treated with VEGFA_164 were not different compared to mice 
receiving control treatment (Schmidt et al., 2006). The role of VEGF in production of 
testosterone is still unclear. In the current study, testosterone levels in three VEGFA-
DSertG mice were 10 fold higher compared to controls. In VEGFA-DSertG mice, both 
VEGF angiogenic and inhibitory isoforms were knocked out in Sertoli cells and some 
germ cells. Loss of VEGF in Sertoli cells may affect the Leydig cell function and then 
cause the increase in serum testosterone.  
        In testis, LH secreted from anterior pituitary through cAMP, stimulates synthesis 
and release of testosterone by the Leydig cells. Aromatase converts testosterone to 
estrogen. We did aromatase immunohistochemistry in the testis. Some studies reported 
that estrogen is synthesis in Leydig cells and germ cell in the mouse (Wang et al., 2001; 
Bilinska et al., 2003; Carreau et al., 2003; Hess and Carnes, 2004). In our studies, 
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aromatase located in Leydig cells in the interstitial area, some germ cells and Sertoli cells. 
VEGFA-DSertG testis aromatase did not present a difference compared to the controls. 
QPCR showed that aromatase mRNA in VEGFA-DSertG testis was not different with 
that in control. It is possible since we were only knocking out VEGFA in Sertoli cells that 
we were unable to detect differences in genes that are not specific to Sertoli cells. The 
result indicated that in VEGFA-DSertG mice, the VEGFA loss influenced the 
testosterone production via other enzyme or pathways potentially not through aromatase.  
        Body growth and male accessory gland organ development are affected by the 
testosterone. The increase in testosterone synthesis in male body after birth leads to a 
male pattern of growth hormone secretion and affects body growth. The testosterone 
level might be deficient at certain stages during development in VEGFA-DSertG mice. 
Thus, deficient testosterone may cause the lower weight of the body, testes and 
epididymis in VEGFA-DSertG mice. The VEGFA-DSertG prostate weight also tended to 
be smaller. 
        The epididymis is derived from the Wolffian duct and consists mainly of 
mesenchymal tissue at birth (Cornwall, 2009). Androgens are important for normal 
epididymal morphology and function while LH could be required for certain facets of 
epididymal morphology and function (Lei et al., 2003). In present study, the high 
testosterone in VEGFA-DSertG could reduce the release of LH. Deficient LH may affect 
the epididymal growth. Another possibility for smaller epididymis is that the testosterone 
level might be deficient at stages during epididymal development.  
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        Besides androgens, the development of differentiated epithelium also requires the 
influence of luminal factors from the testis (Rodriguez et al., 2002) which are poorly 
understood. Ductus epididymidis was dilated in the VEGFA overexpressing transgenic 
mice. The number of subepithelial capillaries in the epididymis was increased in 
transgenic mice. This indicated that VEGFA is involved in the vessel development in 
epididymis (Korpelainen et al., 1998). In current study, Sertoli cell-specific VEGFA loss 
may affect epididymal growth through influencing vessel development and permeability 
which could reduce epididymal size.  
        The prostate is an androgen target organ whose growth, morphology, and function 
are dependent on the androgens produced by the testes. Five-α-dihydrotestosterone (DHT) 
stimulates the development and growth of the prostate, but is not essential for prostatic 
bud formation (Mahendroo et al., 2001). Androgens are required for prostatic 
development through the androgen receptor (Wilson et al., 1995) and mesenchyme drives 
prostatic epithelial development (Thomson et al., 2008). Regional differences in 
branching morphogenesis and cytodifferentiation are controlled by the instructional 
influences of mesenchyme and temporal expression of growth factors (Timms et al., 
2008).  Sertoli cell-specific VEGFA loss may affect the size of prostate through DHT 
which was not measured in the present study. Branching morphogenesis in VEGFA-
DSertG was abnormal, suggesting prostate development may be altered by hormones or 
reduced growth factors. 
        In the present study, the time period from mating to parturition in female VEGFA-
DGranG X VEGFA-DSertG mice was longer compared to the control. This increase in 
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time to pregnancy may be caused by problems with the reduction in female ovulation or 
reduction in spermatogenesis or potentially reduced sperm cell viability due to less than 
optimal seminal fluid quality. VEGFA-DSertG mice may lose expression of VEGFA in 
some germ cells. VEGFA concentration in human semen is a factor that predicts 
pregnancy success following IVF. Thus, too high or too low VEGFA in human semen is 
also related to pregnancy failure (Huminiecki et al., 2001) and may contribute to the 
longer time to conceive and have pups in our KO models.  
        Removal of VEGFA in Sertoli cells caused mice to be sub-fertile and resulted in 
smaller body size, testis and epididymis. The serum testosterone level also tended to be 
high in VEGFA-DSertG. In VEGFA-DSertG mice, the morphology of epididymis and 
prostate was also altered. Sertoli cell-specific VEGFA loss also increased the Bcl-2 and 
Sin3a expression in testis. Therefore, VEGFA plays an important role in male 
reproductive organ morphogenesis and function for mice. 
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Figure Legends 
 
Table 1. Quantitative Real-time PCR primers, probes and kit. 
 
Figure 1. Effect of Sertoli cell-specific VEGFA loss on the weights of male body (G) and 
testes (H). Histological images of sections (H&E stained) of control testis (A, C, E) and 
VEGFA-DSertG testis (B, D, F). The mean weights + SEM are presented. * denotes 
significant difference at P < 0.05. 
 
Figure 2. Expression of Bcl-2 (A), Bax (B) and the ratio of Bcl-2/Bax (C) and Sin3a (D)  
mRNA in testis. Figure E is amount of Sin3a mRNA in VEGFA-DSertG males with high 
testosterone. The mean normalized values + SEM are presented. ** denotes significant 
difference at 0.05 < P < 0.1. * denotes significant difference at P < 0.05. 
 
Figure 3. Effect of Sertoli cell-specific VEGFA loss on serum testosterone concentration 
(G). Three VEGFA-DSertG males had 10 fold greater testosterone concentrations than 
controls (H). Aromatase IHC in control testis (A, C) and VEGFA-DSertG testis (B, D). 
Negative control in IHC for control testis (E) and VEGFA-DSertG testis (F). Expression 
of Aromatase mRNA in the testis (I). The mean serum concentrations + SEM are 
presented. The mean normalized values + SEM are presented. ** denotes significant 
difference at 0.05 < P < 0.1. 
 
Figure 4. VASA immunohistochemistry in testis. VASA (a known germ cell marker) 
IHC in control testis (A, C) and VEGFA-DSertG testis (B, D). Negative control in IHC 
for control testis (E) and VEGFA-DSertG testis (F). 
 
Figure 5. Effect of Sertoli cell-specific VEGFA loss on weight of epididymis (G). 
Histological images of sections (H&E stained) of control epididymis (A, C, E) and 
VEGFA-DSertG epididymis (B, D, F). The mean weights + SEM are presented. * 
denotes significant difference at P < 0.05. 
 
Figure 6. Effect of Sertoli cell-specific VEGFA loss on weight of prostate (G). 
Histological images of sections (H&E stained) of control prostate (A, C, E) and VEGFA-
DSertG prostate (B, D, F). The mean weights + SEM are presented. ** denotes 
significant difference at 0.05 < P < 0.1. 
 
Figure 7. Time from mating control female with control male to parturition VS time 
from mating VEGFA-DGranG females with VEGFA-DSertG males to parturition. There 
were 5 KO groups and 9 control groups. The mean days from mating to parturition + 
SEM are presented. * denotes significant difference at P < 0.05. 
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Gene Forward Primer Probe 
Dye 
Probe 
Vendor 
Reverse Primer 
Gapdh Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems Catalog #4308313 
(VIC Probe) 
Bcl-2 CGTTGGCCCTTCGGAGT
T 
FAM Applied 
Biosystems 
TCAGACCTCCAGGGCAGAGA 
Bax GGCCTTTTTGCTACAGG
GTTT 
FAM Applied 
Biosystems 
GTGTCTCCCCAGCCATCCT 
Sin3a Kit-Taqman Gene Expression Assay Mm00488255_m1 (FAM Probe) 
Aromatase AACCCGAGCCTTTGGAG
A 
FAM Applied 
Biosystems 
GGCCCGTCAGAGCTTTCA 
 
 
 
 
 
 
 
 
 
Table 1. 
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Appendix A: VEGFA Conditional Knockout Breeding Scheme 
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Appendix B: Conventional PCR primers and programs for genotyping    
Gene Primer PCR program 
Dmrt-1 Forward 5`-AGCAGAGGCTTCCTTCGACTT-3`     1 94°C 4:00 
 2 94° 1:00 
 3 60° 0:15 
 4 72° 0:15 
 5 Go to 2     30 times 
 6 2° 5:00 
 7 4°              forever 
Reverse 5`-AGTGAACGAACCTGGTCGAAA-3` 
VEGFA
lox/loxp Forward 
VEGFA419 
5`-CCTGGCCCTCAAGTACACCTT-3`     1          50°C 2:00 
 2 95°                  10:00 
 3 95° 0:15 
 4 57° 1:00 
 5 72° 2:00 
 6 Go to 3        34 times 
 7 72° 3:00 
 8 4°                  forever 
Reverse 
VEGFA567 
5`- TCCGTACGACGCATTTCTAG-3` 
Sry Forward 5`-CGGGATCCATGTCAAGCGCCCCATGA-3`      1 94°C 1:00 
 2 94° 1:00 
 3 58° 1:00 
 4 72° 1:00 
 5 Go to 2         29 times 
 6 72° 5:00 
 7 4°                    forever 
Reverse 5`- GCGGAATTCACTTTAGCCCTCCGATG-3` 
 
 
 
 
 
 
 
 
 
 
    104 
 
Summary 
        In this thesis, we have demonstrated that the effects of Granulosa and Sertoli-cell 
specific VEGFA loss on gonads, male accessory gland, organ function and 
morphogenesis in vivo. We believe that the data in this thesis support our hypothesis that 
VEGFA is critical for normal gonadal morphogenesis and function. 
        We utilized Cre-lox technology to knockout VEGFA in female Granulosa cells, 
male Sertoli cells and sub-populations of germ in mice. We are the first to generate the 
female Granulosa cell (VEGFA-DGranG), and male Sertolic cell-specific (VEGFA-
DSertG) VEGFA loss mice. In our conditional knockout mice both VEGFA pro-
angiogenic and anti-angiogenic isoforms were removed. 
        We have identified that removal of VEGFA in Granulosa cells within ovaries 
resulted in smaller ovary, fewer CL, abnormal CL structure, and reduced 17beta-estradiol 
concentrations in blood plasma. Removal of VEGFA in VEGFA-DSertG males affected 
body weight, size of the testis, epididymis and prostate, as wells as increasing 
testosterone concentrations (in three KO mice). In addition, Bcl-2 mRNA expression also 
tended to be increased in VEGFA-DSertG testis when compared to controls and Sin3a 
mRNA was increased in those three VEGFA-DSertG males with high serum testosterone 
concentration than controls. Sertoli cell-specific VEGFA loss affected the morphology of 
epididymis and prostate with fewer tubules in the epidiymus and reduced branching in 
the prostate. The time period from mating to parturition in female VEGFA-DGranG X 
male VEGFA-DSertG mice was longer compared to the control. This longer time to 
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conception may be due to reduced ovulation of the VEGFA-DGranG female mice and /or 
reduced quantity or quality of sperm in VEGFA-DSertG mice.  
        In summary, lack of VEGFA in Granulosa and Sertoli cells causes altered 
reproductive gonadal morphogenesis, reduced gonadal and male accessory gland organ 
weights, changed steroidogenic profiles and potentially caused subfertility in both male 
and female mice. 
 
 
 
